IE52768B1 - 1-arylcyclobutylalkylamine compounds useful as therapeutic agents - Google Patents

1-arylcyclobutylalkylamine compounds useful as therapeutic agents

Info

Publication number
IE52768B1
IE52768B1 IE481/82A IE48182A IE52768B1 IE 52768 B1 IE52768 B1 IE 52768B1 IE 481/82 A IE481/82 A IE 481/82A IE 48182 A IE48182 A IE 48182A IE 52768 B1 IE52768 B1 IE 52768B1
Authority
IE
Ireland
Prior art keywords
formula
compounds
ether
carbon atoms
give
Prior art date
Application number
IE481/82A
Other versions
IE820481L (en
Original Assignee
Boots Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26279045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE52768(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Ltd filed Critical Boots Co Ltd
Publication of IE820481L publication Critical patent/IE820481L/en
Publication of IE52768B1 publication Critical patent/IE52768B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/147Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40Halogenated unsaturated alcohols
    • C07C33/50Halogenated unsaturated alcohols containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/42Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrolysis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/44Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/237Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/567Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16Unsaturated compounds
    • C07C61/40Unsaturated compounds containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

Compounds of formula I in which n=0 or 1; R1 is C1- alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl when n=0 or R1 is H or C1-3 alkyl when n=1, R2 is H or C1-3 alkyl, R3 and/or R4 are H, formyl, C1-3 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl or R3 and R4 together with the nitrogen atom form a heterocyclic ring system; R5 and/or R6 are H, halo, CF3, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylthio or R5 and R6 together with the carbon atoms to which they are attached form a second benzene ring and R7 and/or R8 are H or C1-3 alkyl show therapeutic activity in the treatment of depression. Pharmaceutical compositions and processes for preparing compounds of formula I are disclosed.

Description

This invention relates to compounds having useful therapeutic activity particularly hut not exclusively as antidepressants, to pharmaceutical compositions containing such compounds and to processes for the preparation of such compounds.
The present invention provides compounds of formula I in which n = 0 or 1; in which, when n = 0, is a straight or branched chain alkyl group containing 1 to 6 carbon atoms, a cycloalkyl group containing 3 to 7 carbon atoms, a cycloalkylalkyl group in which the cycloalkyl group contains 3 to 6 carbon atoms and the alkyl group contains 1 to 3 carbon atoms, an alkenyl group or an alkynyl group containing 2 to 6 carbon atoms or a group of formula II R10 II *9 53768 in which Rg and Rj_q, which may be the same or different, are H, halo or an alkoxy group containing 1 to 3 carbon atoms; in which, when n = 1, R^ is H or an alkyl group containing 1 to 3 carbon atoms; in which Rg is H or an alkyl group containing 1 to 3 carbon atoms; in which R^ and RZ(7 which may be the same or different, are H, a straight or branched chain alkyl group containing 1 to 4 carbon atoms, an alkenyl group having 3 to 6 carbon atoms, an alkynyl group having 3 to 6 carbon atoms, a cycloalkyl group in which the ring contains 3 to 7 carbon atoms, a group of formula R-^CO where R-q is H or R^ and R^ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring having 5 or 6 atoms in the ring which optionally contains further hetero in addition to the nitrogen atom; in which R~ and Rg, which may be the same or different, are H, halo, trifluoromethyl, an alkyl group containing 1 to 3 carbon atoms, an alkoxy or alkylthio group containing 1 to 3 carbon atoms, phenyl, or Rg and .Rg, together with the carbon atoms to which they are attached, form a second benzene ring which may be substituted by one or more halo groups, an alkyl or alkoxy group containing 1 to 4 carbon atoms or the substituents of the second benzene ring together with the two carbon atoms to which they are attached may form a further benzene ring; and in which R? and RQ which may be the same or different are H or an alkyl group containing 1 to 3 carbon atoms; and their pharmaceutically acceptable salts.
In the formulae included in this Specification the symbol represents a 1,1-disubstituted cyclobutane group of formula S 8 - 4 and -CR^RgXCRyRg-JjjNR^R^ represents a. group of formula In the preferred compounds of formula I In which n=0, R^ is a straight or branched chain alkyl group containing I to. 4 carbon atoms, a cycloalkyl group containing 3 to 7 carbon atoms, a cycloalkylmethyl group in which the cycloalkyl ring contains 3 to 6 carbon atoms or a group of formula II in which Rg and/or R^q are H, fluoro or methoxy and In which R2 is H or methyl. Examples of particularly preferred compounds of formula I are those'in which when'n = 0 and R2 is H, R^ is methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropylmethyl, cyclobutylmethyl, cyeLopentylmethyl, cyclohexylmethyl and phenyl.
In the preferred compounds of formula I in which n = 1, R^ is H or methyl, and Rg is H.' In particularly preferred compounds of formula I in which n = 1 both R^ and R2 are H.' In preferred compounds of formula I, Rj and/or R^ are hydrogen, methyl, ethyl or formyl or, when R^ and R^ together with the nitrogen atom to which they are attached form a heterocyclic ring, the preferred compounds of formula I contain a heterocyclicgroup containing one nitrogen atom and 4 or 5 carbon atoms’(e.g.pyrrolidinyl, .piperidino) which is optionally substituted by one or more alkyl (e.g. methyl) groups (e.g. pyrrolidinyl substituted by two methyl groups), a heterocyclicgroup containing a second nitrogen atom which is optionally alkylated (e.g. 4-methylpiperazinyl)or a heterocyclic group including one or more double bonds (e.g. 1,2,3,6-tetrahydropyridyl). In particularly preferred compounds of formula I R^ and/or R^ are H, methyl, ethyl and formyl.
In preferred compounds of formula I R^ and/or Rg are H, fluoro, chloro, bromo, iodo, trifluoromethyl, methyl, methoxy, phenyl or Rg and Rg together with the carbon atom to.which they are attached form a second benzene ring which may optionally be substituted by halo. 53768 - 5 A first group of preferred compounds of represented by formula III formula I is CR-jR^CR^g^NR^ I III in which R^ and Rg are as defined above. In preferred com5 pounds of formula III R^ and Rg which may be the same or different, are H, fluoro, chloro,'bromo, iodo, trifluoromethyl, methyl, methoxy , phenyl or in which R^ and. Rg together with the carbon atoms to which they are attached form a second benzene ring which-may lo optionally be substituted by a chloro group. In particularly preferred compounds of formula III R^ and/or Rg are-H, fluoro, chloro, iodo, trifluoromethyl, methyl, phenyl or R^ and Rg together with the carbon atoms to which they are attached form a second benzene ring which may optionally be substituted by a chloro group.
A second group of preferred compounds of formula I is represented by formula IV in which R^ may he H, fluoro, chloro, bromo, iodo, trifluoro20 methyl, methyl, methoxy or phenyl and in which Rg is fluoro or methyl. In particularly preferred compounds of formula IV Rg is H or chloro.
In preferred compounds-of formula I in which n = 1, R? is H, methyl or ethyl and Rg is H and in particularly pre25 ferred compounds of formula I Ry is H or ethyl and Rg is H.
Compounds of formula I may exist as salts with pharmaceutically acceptable acids. Examples of such salts include hydrochlorides, maleates, acetates, citrates, fumarates, tartrates, succinates and salts with acidic amino 30 acids such as aspartic and glutamic acids. 53768 - β Compounds of formula I which contain one or more asymmetric carbon atoms can exist in different optically active forms. When R^ and Rg are different or R? and Rg are different, the compounds of formula I contain a chiral centre. Such compounds exist in two enantiomeric forms and the present invention includes both enantiomeric forms and mixtures thereof. When both R^ and Rg are different and Ry and Rg are different, the compounds of formula I contain two chiral centres and the compounds exist in four diastereoisomeric forms. The present invention includes each of these diastereoisomeric forms and mixtures thereof.
The present invention also includes pharmaceutical compositions containing a therapeutically effective amount of a compound of formula I together with a pharmaceutically acceptable diluent or carrier.
In therapeutic use, the active compound may be administered orally, rectally, parenterally or topically, preferably orally. Thus the therapeutic compositions of the present invention may take the form of any of the known pharmaceutical compositions for oral, rectal, parenteral or topical administration. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The compositions of the invention . may contain 0.1-90% by weight of active compound. The compositions of the invention are generally prepared in unit dosage form.
Compositions for oral administration are the preferred compositions of the invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, syrups and aqueous or oily suspensions.
The excipients used in the preparation of these compositions are the excipients known in the pharmacists' art. Tablets may be prepared by mixing the active compound with an inei’t diluent such as calcium phosphate in the presence of disintegrating agents, for example maize starch, and lubricating 35 agents, for example magnesium stearate, and tableting the - 7 mixture by known methods. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by conventional means and. if desired, provided with enteric coatings in a known maimer. The tablets and capsules may conveniently each contain 1 to 500 mg of the active compound. Other compositions for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxymethylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.
Compositions of the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example suppositories with cocoa butter or polyethylene glycol bases.
Compositions of the invention suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions in aqueous and oily media or sterile solutions in a suitable solvent.
Compositions for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream or ointment base.
In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling. - 8 In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
The pharmaceutical compositions containing a thera5 peutically effective amount of a compound of formula I may be used to treat depression in mammals including human beings.
In such treatment the amount of the compound of formula I administered per day is in the range 1 to 1000 mg preferably 5 to 500 mg.
Compounds of formula I in which is CHO may be prepared by the reductive amidation of ketones of formula V or of ketones or aldehydes of formula VI for example with formamide and formic acid or ammonium formate and formic acid to give compounds of formula I in which is CHO and is H or with formamides of formula HCONHR^ in which is an alkyl or cycloalkyl group and formic acid or amines of formula R^KH2in which R^ is an alkyl or cyclo20 alkyl group and formic acid.
Compounds of formula I in which R^ is CHO may be prepared by the formylation of compounds of Formula I in which R^ is H for example by reaction with methyl formate.
Compounds of formula I in which R-j is other than H and 25 R^ is CHO may be prepared by reacting compounds of formula I in which Rj is H and is CHO with a compound of formula R^X where X is a leaving group such as a halo group in the presence of a base. - 9 Compounds of formula I may be prepared by the reductive amination of ketones of formula V or of ketones or aldehydes of formula VI. Examples of suitable reductive amination processes are given below:5 a) for compounds of formula I in which R^ and are H, by reaction of the ketone or aldehyde with an ammonium salt for example ammonium acetate and a reducing agent such as sodium cyanoborohydride, b) for canpounds of formula I in which Rj is alkyl or cycloalkyl and R4 10 is H by reaction of the ketone or aldehyde with an amine of formula RgNH2 and a reducing agent such as sodium cyanoborohydride or sodium borohydride. c) for compounds of formula I in which neither Rg nor R^ is hydrogen or in which Rg ana R^ together with the nitrogen 15 atom form a heterocyclic ring, by reaction of the ketone or aldehyde with an amine of formula KNRgR^ and either formic acid or a reducing agent such as sodium cyanoborohydride, d) for compounds of formula I in which one or both of Rg and R^ are H or an alkyl or a cycloalkyl group or in which Rg 2o and R^ together with the nitrogen atom form a heterocyclic ring, by catalytic hydrogenation at elevated temperature and pressure of a mixture of the ketone or aldehyde and an amine of formula HNR,R,.
Compounds of formula I in which Rg and R^ are both alkyl groups may be prepared by reacting a ketone of formula V or a ketone or aldehyde of formula VI with a dialkyl formamide of formula HCONRgR^ for example in the presence of formic acid.
Compounds of formula I may be prepared by the reduction of compounds of formula VII VII 2768 -loin which a) Z is a group of formula - CRUNCH or an ester or ether thereof to give compounds of formula I in which n = 0 and R2, R^ and R^ are H; b) Z is a group of formula - CR-^=KR^ (where R^ is other than H or OKI) togive compounds of formula I in which n = 0 and and R^ are H; c) Z is a group of formula - CR^=NY in which Y represents a metal-containing moiety derived from an organometallic reagent and Rc to give compounds of formula I in which n R^ are H; d) Z is a group of formula - CR-^R^CN to give compounds of R, and b formula I in which n - 1 and R^, R^, Ry and Rg are H; e) Z is a group of formula - CR-jR-jCR^NOH or an ester or ether thereof to give compounds of formula I in which n = 1 and Ry R^ and Ηθ are H; f) Z is a group of fonnula - (where Rg is other than H or CHO) to give compounds of formula I in which n = 1 and R^ and Rg are H; g) Z is a group of formula - CR-^R^CRy=NY in which Y represents a metal-containing moiety derived from an organometallic reagent to give compounds of formula I in which n = 1 and R^, and RQ are H; h) Z is a group of formula - CR^R^COMR^R^ to give compounds of formula I in which n = 1 and R? and Rg are H.
Suitable reducing agents for the above reactions include sodium borohydride, sodium cyanoborohydride, lithium aluminium hydride or borane-dimethylsulphide complex.
In (c) and (g) above Y is preferably MgBr derived from a Grignard reagent or Li derived from an organolithium compound. - 11 53768 Compounds of formula I in which n = 0 may be prepared by the reaction of an organometallic reagent for example a Grignard reagent of formula R-jMgX where X is Cl, Br or I or an organolithiuin compound of formula R.Li with imines of formula VIII CH=NR, VIII followed by hydrolysis to give secondary amines of formula I. In a similar manner imines of formula IX may be converted to secondary amines of formula I in which n = 1 Compounds of formula I in which R^ are H raa^ be prepared by the decarboxylative rearrangement, for example using iodosobenzene-oistrifluoroacetate or by a Hofmann reaction using bromine in alkaline solution, of amides of formula X or amides of formula XI Rg CR^RgCODK^ XI to give amines of formula I in which n = 0 and n = 1 respectively.
V 2768 - 12 Compounds of formula I in which and R^ are R may be prepared by the decarboxylative rearrangement of acyl azides in the Curtius reaction. The acyl azides may be formed for example by reaction of acid chlorides of formula XII or acid chlorides of formula XIII with sodium az-Ma Compounds of formula I in which R^ and R^ are H may be prepared by a Schmidt reaction in which carboxylic acids of formula XIV or carboxylic acids of formula XV react with hydrazoic acid Compounds of formula I in which R^ is H may be prepared 15 by hydrolysis of compounds of formula I in which R^ is CHO, for example by acid hydrolysis.
Compounds of formula I in which R^ is methyl may he prepared by reduction of compounds of formula I in which R^ is CHO, for example by lithium aluminium hydride or by sodium bis (2-methoxyethoxy)aluminium hydride. - 13 Compounds of formula I in which one or both of R^ and is other than H may be prepared from compounds of formula I in which one or both of R^ and R^ are hydrogen by methods which are well known in the art for the conversion of prim5 ary to secondary or tertiary amines or for the conversion of secondary to tertiary amines. The following are given as examples of suitable processes:a) by alkylating primary amines of formula I to give secondary amines of formula I for example by a process which includes the steps of protecting the primary amine with a protecting group such as trifluoroacetyl, alkylating with an alkyl halide and removing the protecting group for example by hydrolysis; b) by alkylating primary amines of formula I, for example, with an alkyl halide to give tertiary amines of formula I in which R^ and R^ are the same; c) by alkylating secondary amines of formula I, for example, v/ith an alkyl halide to give tertiary amines of formula I in which R^ and R^ may be different: d) by reacting primary amines of formula I with sodium borohydride and acetic acid to give secondary amines of formula I in which R^ is ethyl and R^ is H; e) by reacting primary amines of formula I with formaldehyde and formic acid to give tertiary amines of formula I in which both and R^ are methyl f) by reacting secondary amines of formula I in which is H with formaldehyde and formic acid to give tertiary amines of formula I in which R^ is methyl g) by formylating primary amines of formula I, for example by reaction with methyl formate, and reducing the resulting formamides, for example with lithium aluminium hydride to give secondary amines of formula I in which R-j is methyl and R^ is H; - 14 h) by formylating secondary amines of formula I, for example by reaction with methyl formate, and reducing the resulting formamides, for example with lithium aluminium hydride to give tertiary amines of formula I in which is methyl. i) by acylating primary amines of formula I, for example by reaction with an acyl chloride of formula R^9COC1 or an anhydride of formula (R-^COjgO in which R12 is an alkyl, alkenyl or alkynyl group and reducing the resulting amides for example with lithium aluminium hydride to give secondary amines of formula I in which R^ is -CH2R-^2 and R^ is H. j) by acylating secondary amines of formula I in which R^ is H for example by reaction with an acyl chloride of formula R12COC1 or an anhydride of formula (R12C0)2O in which R12 is an alkyl, alkenyl or alkynyl group and reducing the resulting amides for example with lithium aluminium hydride to give tertiary amines in which R^ is CHgR^. k) by reacting primary amines of formula I with an aldehyde of formula R-^CHO in which R^ may 311 alkyl group, an alkenyl or alkynyl group or a ketone of formula R14COR15 in which and R^ which may be the same or different are an alkyl group, alkenyl group, alkynyl group or R^ and R^ together with carbon atom to which they are attached may form an alicyclic ring and reducing the resulting imines or enamines for example with sodium cyanoborohydride or, when R13’ R14 or R15 are not or alkynyl, by catalytic hydrogenation to give secondary amines of formula I in which λ15 Rj is R-^CHg- and CH- respectively; 1) by reacting primary amines of formula I with a nongeminally disubstituted alkane containing 2 or 3 carbon atoms between the carbon atoms carrying the substitutents which may be for example halo preferably bromo, or p-toluenesulphonyloxy to give compounds of formula I in which R^ and R^ together with the nitrogen to which they are attached form a heterocyclic ring containing no heteroatoms other than the nitrogen atom. 53768 - 15 The ketones of formula V may be prepared by the hydrolysis of imines of formula XVI in which Y represents a metal-containing moiety derived from 5 an organometallic reagent. iChe imines of formula XVI mav be prepared by the reaction of said organometallic reagent with a cyano compound of formula XVII Suitable organometallic reagents include Grignard reagents 10 of formula R-jMgX where X is Cl, Br or I (Y = MgX) and organolithium compounds of formula R^Li (Y = Li).
The ketones of formula VI may be prepared by the hydrolysis of imines of formula XVIII R.
CR^gCR^NY □ XVIII in which Y represents a metal-containing moiety derived from an organometallic reagent. The imines of formulaXVIIImay be prepared by the reaction of the said organometallic reagents with cyano compounds of formula XIX CI^RgCN XIX - 16 Suitable organometallic reagents include Grignard reagents of formula RyMgX where X is Cl, Br or I (Y = MgX) and organolithiuin compounds of formula R-^Li (Y =Li).
Ketones of formula V may be prepared by the reaction of 5 carboxylic acid derivatives such as an amide or acid halide with an organometallic reagent for example by the reaction of an acid chloride of formula XX with a Grignard reagent of formula RJflgX where X is Cl, Br or 10 I at low temperatures or 'by the reaction of a carboxylic acid with an organometallic reagent, for example an organolithiuin compound of formula R^Li.
Ketones of formula VI may be prepared by the reaction of carboxylic acid derivatives such as an amide or acid halide with an organometallic reagent for example by the reaction of an acid chloride of formula XII with a Grignard reagent of formula RyMgX where X is Cl, Br or I at low temperatures or by the reaction of a carboxylic acid of formula XIV with an organometallic reagent for example an organolithiuin compound of formula RyLi.
Ketones of formula V in which Rj is alkyl (e.g. methyl) and ketones of formula VI in which. Ry is alkyl (e.g. methyl) may be prepared by the reaction of a diazoalkane (e.g. diazomethane) with aldehydes of formula XXII and VI respectively. 53768 Ri CHO XXII Aldehydes of formula VI may be prepared by methods well known in the art. The following are given as examples of suitable methods:5 a) by reduction of cyano compounds of formula XIX with for example di-tert-butylaluminium hydride dr di-isobutylaluminium hydride. b) by the reduction of carboxylic acid derivatives for example:10 i) by reduction of compounds of formula VII in which Z is CR^RgCOMR^R^ R^ are other than H for example by using lithium diethoxyaluminohydride. ii) by reduction of amides formed by the reaction of ethyleneimine with an acid chloride of formula XII for example using lithium aluminium hydride as the reducing agent. ili) by the reduction of acid chlorides of formula XII for example with lithium tri-tertbutoxyaluminohydride. c) by the reaction of alcohols (formed by the reduction of carboxylic acids of formula XIV) with, for example, chromiun trioxide-pyridine complex in dichloromethane under anhydrous conditions. - 18 Compounds of formula VII in which Z is a group of formula -CR^=NOH or -CR^RgCR^NOH or ethers or esters thereof may be prepared by the reaction of hydroxylamine or an ether or ester thereof with ketones of formula V and ketones or aldehydes of formula VI respectively.
Compounds of formula VII in. which Z is a group of formula -CR^=NRg or -CR^Rg.CR^NRg may be prepared by the reaction of amines of formula NHgRg with ketones of formula V and ketones or aldehydes of formula VI respectively.
The preparation of compounds of formula VII in which Z is a group of formula -CR-L=N'f or -CR1R2PRy=NY has been described above in respect of compounds of formula XVI and XVIII respectively.
The preparation of compounds of formula VII in which Z is a’ group of formula -CR-, RgCN will be described hereinafter in respect of the cyano compounds of formula XIX.
Compounds of formula VII in which Z is a group of formula -CR-jRgCONRgR^ may be prepared by the reaction of acid derivatives such as esters or acid halides (for example 20 acid chlorides of formula XII) with amines of formula HNRgR^. Compounds of formula VII in which Z is CR^RgCONHg may be prepared from cyano compounds of formula XIX for example by hydration, with aqueous acids or by reaction with hydrogen peroxide in the presence of a base.
Imines of formula VIII and IX may be prepared by reaction of amines of formula RgNH2 with aldehydes of formula XXII and VI respectively. - 19 Amides of formula X may be prepared by the reaction of ammonia with carboxylic acid derivatives for example acid chlorides of formula XII or they may be prepared from cyano compounds of formula XIX for example by hydration with aqueous acids or by reaction with hydrogen peroxide in the presence of a base.
Amides of formula XI may be prepared by the reaction of ammonia with carboxylic acid derivatives for example acid chlorides of formula XIII or they may be prepared from cyano compounds of formula XXIII for example by hydration with aqueous acids or by reaction with hydrogen peroxide in the presence of a base.
Amides of formula X in which and Rg are H and amides of formula XI in which R? and Rg are H may be prepared from acid chlorides of formula XX and XII respectively by reaction with diazomethane to form a diazoketone which rearranges in the presence of ammonia and a catalyst for example silver to give the required amide.
Carboxylic acids of formula XIV, XV and XXI may be prepared by the hydrolysis, for example basic hydrolysis, of cyano compounds of formula XIX, XXIII and XVII respectively. Carboxylic acids of formula XIV and XV may be prepared by the reaction of amides of formula X and XI respectively with nitrous acid. Carboxylic acids of formula XXI may be prepared by the reaction of nitrous acid with the amides formed by the reaction of ammonia with carboxylic acid derivatives for example acid chlorides of formula XX or by the reaction of cyano compounds of formula XVII with hydrogen 3o peroxide in the presence of a base. - 20 Carboxylic acids of formula XIV in which R-^ and R,, are H and carboxylic acids of formula XV in which Ry and Rg are H may be prepared from acid chlorides of formula XX and XII respectively by reaction with dia5 zomethane to form diazoketones which rearranges in the presence of water and a catalyst for example silver to give the required acid.
Cyano compounds of formula XVII may be prepared by the reaction of cyano compounds of formula XXIV XXIV with a 1,3-disubstituted propane for example 1,3-dibromopropane and a base such as sodium hydride.
Cyano compounds of formula XIX in which R^ and R^ are H may be prepared from cyano compounds of formula XVII by for example the following series of reactionsία) hydrolysis of the cyano group to form a carboxylic acid of formula XXI; b) reduction of the carboxylic acid for example with lithium aluminium hydride or borane-dimethyisulphide complex to form the corresponding alcohol; 53768 - 21 c) replacement of the hydroxy group of the alcohol by a leaving group for example a £-toluene sulphonyloxy group and d) replacement of the leaving group with a cyano group.
In a similar manner cyano compounds of formula XXIII may be prepared from cyano compounds of formula XIX.
Cyano compounds of formula XIX in which one or both of R^ and R2 are other than H may be prepared from the corresponding cyano compounds of formula XIX in which and/or R2 are H, for example by alkylation with an alkyl halide in the presence of a base such as lithium diisopropylamide. In a similar way cyano compounds of formula XXIII in which one or both of R-, and Rg are other than hydrogen may be prepared from compounds of formula XXIII in which R? and Rg are both H.
Cyano compounds of formula XIX in which R2 = H may also be prepared by reacting ketones of formula V or an aldehyde of formula XXII with a reagent for introducing a cyano group such as £-toluenesulphonyImethyl isocyanide.
In a similar manner cyano compounds of formula XXIII may be prepared from aldehydes or ketones of formula VI.
Acid chlorides of formulae XX, XII and XIII may be prepared by the reaction of carboxylic acids of formulae XXI, XIV and XV respectively with for example thionyl chloride.
Aldehydes of formula XXII may be prepared by methods well known to those skilled in the art. The following are given as examples of suitable methods:a) by the reduction of cyano compounds of formula XVII with for example di-tert-butylaluminium hydride or diisobutylaluminium hydride. b) by the reduction of carboxylic acid derivatives, for example - 22 i) by the reduction of tertiary amides formed by the reaction of secondary amines with acid chlorides of formula XX for example when the secondary amine is a dialkylamine using lithium diethoxyaluminohydride as reducing agent or when the secondary amine is ethyleneimine using lithium aluminium hydride as the reducing agent, ii) by the reduction of acid chlorides of formula XX for example with lithium tri-tert-butoxyaluminohydride. c) by the oxidation of alcohols (prepared by the reduction of carboxylic acids of formula XXI) with, for example, chromium trioxide-pyridine complex in dichloro15 methane under anhydrous conditions.
Novel formamides of formula XXV XXV are described herein as intermediates, in the preparation of 53768 - 23 compounds of formula I and such novel formamides form a further aspect of the present invention.
The therapeutic activity of the compounds of formula I has been indicated by assessing the ability of the compounds to reverse the hypothermic effects of reserpine in the following manner. Male mice of the Charles River CD1 strain weighing between 18 and 30 grammes were separated into groups of five and were supplied with food and water ad libitum. After five hours the body temperature of each mouse was taken orally and the mice were injected intraperitoneally with reserpine (5 mg/kg) in solution in deionised water containing ascorbic acid (50 mg/ml). The amount of liquid injected was 10 ml/kg of body weight. Wine hours aftei· the start of the test food was withdrawn but water was still available ad libitum. Twenty-four hours after the start of the test the temperatures of the mice were taken and the mice were given the test compound suspended in a 0.25% solution of hydroxy ethyl cellulose (sold under the trade name Cellosize OP 15000 by Union Carbide) in deionised water at a dose volume of lOml/kg of body weight. Three hours later the temperatures of all the mice were again taken. The percentage reversal of the reserpine-induced loss of body temperature is then calculated by the formula: (Temperature after 27 hrs - Temperature after 24 hours) X 100 (Temperature after 5 hrs - Temperature after 24 hours) The mean value for each group of five mice was taken at several dose rates to enable a value of the mean dose which causes a 50% reversal (ED50) to be obtained. All the compounds which are the final products of the Examples hereinafter gave values of ED50 of 30 mg/kg or less. It is widely understood by those skilled in the art that this test is indicative of compounds having antidepressant activity in humans.
Table I lists compounds of formula I which gave a value of ED50 in the above test of 10 mg/kg or less. - 24 Table I 1-El—(3,4-dichlorophenylJcyclobutylJethylamine hydrochloride N-methyl-1-Cl-(3,4-dichlorophenyl)cyclobutylJethylamine hydrochloride N,N-dimethyl-1-Cl-(3,4-dichlorophenyl)cyclobutylJethylamine hydrochloride 1-Cl-(4-iodophenylJcyclobutylJethylamine hydrochloride N-methyl-1-Cl-(4-iodophenyl)cyclobutylJethylamine hydrochloride N,N-dimethyl-1-Cl-(4-iodophenyl)cyclobutylJethylamine hydrochloride N-methyl-1-Cl-(2-naphthyl)cyclobutylJethylamine hydrochloride N,N-dimethyl-1-Cl-(4-chloro-3-trifluoromethylphenyl)cyclobutyl Jethylamine hydrochloride 1-Cl—(4-chlorophenyl)cyclobutylJbutylamine hydrochloride N-methyl-1-Cl-(4-chlorophenyl)cyclohutylJbutylamine hydrochloride N,N-dimethyl-1-Cl-(4-chlorophenyl)cyclohutylJbutylamine hydrochloride l-Cl-(3,4-dichlorophenyl)cyclobutylJbutylamine hydrochloride N-methyl-1-Cl-(3»4-dichlorophenyl)cyclobutylJbutylamine hydrochloride N,N-dimethyl-l-Cl-(3,4~dichlorophenyl)cyclobutylJbutylamine hydrochloride 1-Cl-(4-biphenylyl)cyclobutylJbutylamine hydrochloride N,N-dimethyl-1-Cl-(4-biphenylyl)cyclobutylJbutylamine hydrochloride 1-Cl-(4-chloro-3-fluorophenyl)cyclobutylJbutylamine hydrochloride N-formyl-1-Cl-(4-chloro-3-fluorophenyl)cyclobutylJbutylamine 53768 - 25 1-Cl-(3-chloro-4-methylphenyl)cyclobutylJbutylamine hydrochloride N-formyl-1-[l-phenylcyclobutylJbutylamine 1-[l-(3-trifluoromethylphenyl)cyclobutylJbutylamine hydro5 chloride 1- [l-(naphth-2-yl)cyclobutyl Jbutylamine hydrochloride 1-Cl—(6-chloronaphth-2-ylJcyclobutylJbutylamine N-methyl-1-Cl-(4-chlorophenyl)cyclobutylJ-2-methylpropylamine hydrochloride l-Cl-(4-chlorophenyl)cyclobutylJpentylamine hydrochloride N-methyl-1-Cl-(4-chlorophenyl)cyclobutylJpentylamine hydrochloride N,N-dimethyl-1-[l-phenylcyclobutylJ-3-methylbutylamine hydrochloride l-Cl-(4-chlorophenyl)cyclobutylJ-3-methylbutylamine hydrochloride N-methyl-1-Cl-(4-chlorophenyl)cyclobutylJ-3-methylbutylamine hydrochloride N,N-dimethyl-1-Cl-(4-chlorophenyl)cyclobutylJ-3-methyl20 butylamine hydrochloride N-formyl-1-Cl-(4-chlorophenyl)cyclobutylJ-3-methylbutylamine N,N-dimethyl-1-Cl-(3»4-dichlorophenyl)cyclobutylJ-3-methylbutylam'ine hydrochloride N-methyl-1- Cl-(naphth-2-yl)cyclobutyl J-3-methylbutylamine 25 hydrochloride N-methyl-1-Cl-(3,4-dimethylphenyl)cyclohutylJ-3-methylbutylamine hydrochloride Cl-(4-chlorophenyl)cyclobutylJ(cyclopropylJmethylamine hydrochloride N-methyl-Cl-(4-chlorophenyl)cyclobutylJ (cyclopentyl)methylamine hydrochloride Cl-(4-chlorophenyl)cyclobutyl](cyclohexyl)methylamine hydrochloride - 26 10 N-methyl-tl-(4-chlorophenyl)cyclobutylIpyclohexyl)methylam-ipe hydrochloride Cl—(3,4-dichlorophenyl)cyclobutyl Icyclohexyl)methylamine hydrochloride N-methyl-[l-(3,4-dichlorophenyl)cyclobutyll (cyclohexyl)methylamine hydrochloride [l- (4-chlorophenyl )cyclobutyl ](cycloheptyl) methylamine hydrochloride 1-tl—(4-chlorophenyl)cyclobutyl]-2-cyclopropylethylamine hydrochloride N.N-dimethyl-1-[l-(4-chlorophenyl)cyclobutyl]-2-cyclohexylethylamine hydrochloride a-[l-(4-chlorophenyl)cyclobutyl]benzylamine hydrochloride N-methyl-α-tl-(4-chlorophenyl)cyclobutylIbenzylamine hydrochloride 1-tl-(4-chloro-2-fluorophenyl)cyclobutyl]butylamihe N,N-dimethyl-l-[l-(4-chloro-2-fluorophenyl)cyclobutyl] butylamine hydrochloride 1-|tl-(3,4-dichlorophenyl)cyclobutylImethyl^ propylamine hydrochloride N,N-dimethyl-1- £[l-(3,4-dichlorophenyl)cyclobutyl]methylJpropylamine hydrochloride N,N-dimethyl-2-[l-(4-iodophenyl}cyclobutyl]ethylamine hydrochloride N-ethyl-1-[l-(3 > 4-dichlorophenyl)cyclobutyl]ethylamine hydrochloride N,N-diethyl-l-[l-(3»4-dichlorophenyl)oyclobutyl]ethylamine hydrochloride - 27 The Invention will now be illustrated by the following Examples which are given by way of example only. All compounds were characterised by conventional analytical techniques and gave satisfactory elemental analyses. All melting and boiling points are expressed in degrees Celsius.
Example 1 A solution of 3,4-dichlorobenzyl cyanide (25 g) and 1,3-dibromopropane (15 ml) in dry dimethyl sulphoxide (150 ml) was added dropwise under nitrogen to a stirred mixture of sodium hydride (7.5 g) dispersed in mineral oil (7.5 g) and dimethylsulphoxide (200 ml) at a temperature in the range 30 to 35°C. The mixture was stirred at room temperature for two hours and propan-2-ol (8 ml) and then water (110 ml) were added dropwise. The mixture was filtered through a diatomaceous earth sold under the Trade Mark CELITE and the solid residue washed with ether.
The ether layer was separated, washed with water, dried and evaporated. l-(3,4-Dichlorophenyl)-l-cyclobutanecarbonitrile ( b.p. io8-12o°c at 0.15 urn Hg) was isolated by distillation. This method is a modification of that described by Butler and Pollatz (J.Org.Chem., Vol. 36, No. 9, 1971, p.1308).
The 1-(3,4-dichlorophenyl)-l-cyclobutanecarbonitrile prepared as above (21.7 $ was dissolved in dry ether (50 ml) and the solution was added under nitrogen to the product of the reaction of gaseous methyl bromide with magnesium turnings (3.9 g) in dry ether (150 ml). The mixture was stirred at room temperature for two hours and then under reflux for two hours. Crushed ice and then concentrated hydrochloric acid (100 ml) were added and the mixture heated under reflux for two hours. The ether layer was separated, washed with water and aqueous sodium bicarbonate, dried and evaporated. l-Acetyl-l-(3,4-dichlorophenyl)cyclobutane (b.p. 108-110° at 0.2 mm Hg) was isolated by distillation. l-Acetyl-l-(3,4-dichlorophenyl)cyclobutane (9.1 g) prepared as above, formamide (6.5 ml) and 98% formic acid (3 ml) were heated at 180°C for sixteen hours to give N-formyl-152768 - 28 tl— (3,4-dichlorophenyl )cyclobutyl lethylamine. Concentrated hydrochloric acid (20 ml) was added and the mixture heated under reflux for three hours. The solution was then cooled, washed with ether and sodium hydroxide solution added. The product was extracted with ether, and the ether extract washed with water, dried and evaporated. l-tl-(3,4-Dichlorophenyl)oyclobutyllethylamine (b.p. 112-118° at 0.2 mm Hg) was isolated by distillation. The amine was dissolved in propan-2-ol and concentrated hydrochloric acid and the solution evaporated to dryness to give l-[l-(3,4-dichlorophenyl)cyclobutyllethylamine hydrochloride (m.p. 185-195°C). (Formula I n = 0; R^=Me; R2,R3 and R^=H; R^=4-C1; Rg=3-Cl). Example la The preparation of N-formyl-l-[l-(3,4-dichlorophenyl)cyclo butyllethylamine (m.p. 124-125°C) (Example 1(a) Formula I n = 0; R1=Me; R2=H; R3=H; R^CHO; R5=4-C1 and Rg=3-Cl) described above was repeated and the product isolated by cooling the reaction mixture and collecting the solid produced by filtration. The formamide was then hydrolysed by concentrated hydrochloric acid in industrial methylated spirit to give the hydrochloride salt of l-tl-(3,4-dichlorophenyl)cyclobutyllethylamine.
In a similar manner to that described above in Example la the following compounds were prepared. The conditions for the hydrolysis of the formamides which were isolated by appropriate methods are shown in the footnotes.
ExampleR1R5 Rg b.p. (free base) m.p. of HCI salt 1(b) methyl Cl H 107°/1.2 mm Hg 1(c) n-butyl Cl H 138-139° 1(d) methyl I H 205-207° 1(e) methyl Cl cf3 216-217° - 29 A. aqueous HCl/industrial methylated spirit B. The l-valeryl-l-(4-chlorophenyl)cyclobutane was prepared in tetrahydrofuran. Hydrolysis was performed using concentrated HCl/industrial methylated spirit.
C. concentrated HCl/diethyleneglycoldimethyl ether (in a similar manner to that described, later in Example 12).
D. concentrated HCl/industrial methylated spirit.
Example 2 The product of Example 1 (4.04 g), water (0.5 ml) and 98% formic acid.(3.6 ml) were mixed with cooling. 37-40% Aqueous formaldehyde (3.8 ml) was added and. the solution was heated at 85-95°C for five hours. The solution was evaporated to dryness and the residue acidified with concentrated hydrochloric acid and the water removed by repeated addition of propan-2-ol followed by evaporation in vacuo. Crystals of N,N-diraethyl-l-[l-(3,4-dichlorophenyl)cyclobutylJethylamine hydrochloride (m.p. 211-213°C) (Formula I n=0; R^= Me; R2=H; R^.R^ = Me> R^=4-C1; Rg=3-Cl) were isolated.
In a similar way to that described above the compounds of Example 1(b) and 1(d) were converted into the compounds listed below.
Example 2(a) 2(b) 1(b) methyl Cl H 1(d) methyl I H 260-261° b.p. of free base 98-100°/0.5 mmHg Example 3 In a similar manner to that described above in Examples 1 and 2 N,N-dimethyl-l-[l-(4-biphenylyl)cyclobutyl]ethylamine hydrochloride (m.p. 196-197°C) was prepared. (Formula I n=0; R1=Me; R2=H; Rj,R^=Me; R^=4-phenyl and Rg=H). - 30 5 Example 4 l-Acetyl-l-(3,4-dichlorophenyl)cyclobutane (15 g) prepared as described in Example 1, N-methylformamide (47.5 ml) 98% formic acid (10.3 ml) and a 25% aqueous solution of methylamine (1.5 ml) were mixed and heated with stirring at 170-180° for eight hours. The mixture was cooled and extracted with ether. The ether extract was washed, dried and evaporated to yield a light yellow oil which was heated under reflux with concentrated hydrochloric acid (50 ml) for two hours. Industrial methylated spirit (IMS) (50 ml) was added and the mixture heated under reflux for sixteen hours. The mixture was then cooled to 0°C and the white precipitate collected by filtration, washed with acetone and dried. The product, N-methyl-l-[l-(3>4-dichlorophenyl)cyclobutyl]ethylamine hydrochloride, had a melting point of 254 to 256°C (Formula I n = 0; R^ = Me; R2 = H; Rg = Me; R^ = H; Rg = 4-C1 and Rg = 3-Cl). In a similar manner to that described above the follow- ing compounds of formula I were prepared r- =\ CHR.jNHMe.HCi R-Z 7 JR6 ExampleR1R5R6 b.p. of amine m.p. of HCl salt Mote 4(a) Me Cl H 98-100°/0.15 mm Hj 240-241° 4(b) Me H Cl 269-272° 4(c) Me Br H 96-98°/0.1 itm Hg 4(d) Me H Br 251-255° 4(e) 4(f) Me Me CFg H H CFg 219-221° 225-228° 4(g) Me -(CH = ch)2- 254-257° 4(h) Me Cl CFg 198-200° 4(i) Et Cl H 238-240° 4(j) Pr Cl H 228-229° A 4(k) Bu Cl H 152-153° A 4(1) Me I H 242-243° S3768 - 31 Note A The starting ketone was prepared in tetrahydrofuran as reaction solvent in place of ether.
Example 5 A mixture of 70% aqueous ethylamine (50 ml) and water (100 ml) was gradually mixed with a mixture of 98% formic acid (50 ml) and water (100 ml) to give a neutral, solution which was evaporated at 100°C/100 mm Hg until 180 ml of water had been collected. The residue was heated to 14O°C and l-acetyl-l-(4-chlorophenyl)cyclobutane (10.4 g) prepared in a similar manner to that described in Example 1 for 1-acetyl-l-(3,4-dichlorophenyl)cyclobutane and 98% formic acid (10 ml) were added. The mixture was heated, on an oil bath at a temperature of 180-200°C for sixteen hours.
The mixture was distilled until an internal temperature of 170°C was obtained and this temperature was maintained for two hours. Any volatile material was removed by distillation at 16O°C/2O mm and the residue heated under reflux with concentrated hydrochloric acid (15 ml) and industrial methylated spirit (IMS) (15 ml) for three hours. The IMS was evaporated on a rotary evaporator and the residue washed with ether.
The aqueous phase was brought to pH 12 with sodium hydroxide and extracted with ether. The ether extract was dried and on evaporation yielded a residue which was treated with aqueous hydrochloric acid to give N-ethyl-l-[l-(4-chlorophenyl)~ cyclobutyljethylamine hydrochloride (m.p. 203-205°C) (Formula I n = 0; = Me; Rg =H; = Et; R^ = H; R^ = 4-C1; Rg = H).
Example 6 l-(4-Chlorophenyl)-l-cyclobutanecarbonitrile (15 g) prepared in a similar manner to the 1-(3,4-dichlorophenyl)cyclobutanecarbonitrile of Example 1 in dry ether (50 ml) was added to the product of the reaction between magnesium turnings (3.18 g) and propyl bromide (15·99 g) in dry ether (50 ml). The ether was replaced by tetrahydrofuran and the mixture heated with stirring under reflux for eighteen hours. The mixture was cooled and ice and then concentrated hydrochloric - 32 acid. (52 ml) added. The resulting mixture was stirred under reflux for ten hours and extracted with ether. The ether extract yielded a residue from which 1-butyryl-l-(4-chlorophenyl) cyclobutane (b.p. 106-108^0.3 mm Hg) was distilled.
A mixture of the ketone produced as described above (21 g) and 98% formic acid (6 ml) was added over a period of one and a half hours to formamide (15 ml) at 16O°C.
After completion of the addition the temperature was raised to 180 to 185°C and maintained in this range for five hours. The mixture was cooled and extracted with chloroform to yield a thick gum which on heating with petroleum ether (b.p. 60-80°) gave a colourless solid which was recrystallised from petroleum ether (b.p. 60-80°) to yield Nformyl-1-Cl-(4-chlorophenyl)cyclobutylJbutylamine (m.p. 97.5 to 98.5°C) (Formula I n = 0; = propyl; R£ = H; R? = H; R4 = CHO; R5 = 4-C1; Rg = H).
Example 7 A solution of 1-(3,4-dichlorophenyl)-l-cyclobutanecarbonitrile prepared as described in Example 1 (35-2 g) in ether (100 ml) was added to a solution of propyl magnesium bromide prepared by the reaction of propyl bromide (32 g) with magnesium turnings (6.36 g) in ether (100 ml). The ether was replaced by dry toluene and the mixture heated under reflux for one hour. Water (200 ml) and then concentrated hydrochloric acid (120 ml) were added and the mixture heated under reflux for one hour. The reaction mixture was extracted with ether and after washing and drying the extract yielded a residue from which 1hutyryl-l-(3,4-dichlorophenyl)cyclobutane (b.p. 120-128°C at 0.25 mm Hg) was distilled.
The ketone produced as described above (37.0 g) and 98% formic acid (9 ml) were added to formamide (23.5 ml) at 170°C and the temperature kept at 175-180°C for five hours.
A further portion of formic acid (4.5 ml) was added and the mixture was maintained at 175-180°C for a further fifteen hours. The mixture was extracted with ether which - 33 53768 on evaporation gave a thick oil which was crystallised from petroleum ether (b.p. 60-80°) to give N-formyl-1[1-(3,4-dichlorophenyl)cyclobutylIbutylamine having a melting point of 1O3-1O5°C (Formula I n = 0; R1 = propyl; R2 = H; R3 = H; R4 = CHO; Rg = 4-C1 and Rfi = 3-Cl).
In a similar manner to that described above the following compounds were made Example «1R5R6 m.p. (°C) 7(a) isobutyl Cl H 110-112° 7(b) propyl Cl F 115-116° 7(c) phenyl Cl H 94-96° 7(d) propyl H H 98-102° Example 8 The product of Example 7 (4.0 g) in dry tetrahydrofuran (25 ml) was added rapidly to a stirred mixture of lithium aluminium hydride (1.4 g) in dry tetrahydrofuran (25 ml) under nitrogen. The mixture was heated under reflux for five hours and then cooled. Water (15 ml) and then 10% sodium hydroxide solution (3 ml) were added and the mixture filtered through diatomaceous earth sold under the Trade Mark CfiLITE. The product was extracted into ether, back extracted into 5N hydrochloric acid and the aqueous layer was basified and extracted with ether. The ether extract yielded an oil which was dissolved in propan-2-ol (5 ml) and concentrated hydrochloric acid was added to pH 2« Evaporation of the resulting solution gave a white solid which was collected, washed with acetone and dried. The product was N-methyl-1-tl(3,4-dichlorophenyl)cyclobutyl]butylamine hydrochloride and 2768 - 34 had a melting point of 234-235°C (Formula In = Oj Rn = propyl; Rg = H; R^ = H; = Me; R^ = 4-C1 and Rg = 3-Cl) In a similar manner to that described above the following compounds were prepared Example 8(a) 8(b) phenyl Cl propyl Cl R6 H H m.p. (°C) 275-278° 223-228° Example 9 The product of Example 7 (10 g) in solution in ether (50 ml) was added to a 70% toluene solution of sodium bis(2-methoxyethoxy)aluminium hydride sold under the trade mark Red-al (40 ml) at a temperature in the range 25 to 30°C. The mixture was stirred at this temperature for four hours. Water (25 ml) was added dropwise with cooling and the mixture filtered through diatomaceous earth (CELITE). Aqueous NaOH was added and an ether extraction performed. The ether extract was washed with water and back extracted with 5N hydrochloric acid. A white solid (m.p. 232-235°C) appeared at the interface which was collected. Base was added to the aqueous phase and a further ether extraction performed. Evaporation of the ether extract yielded an oil which was dissolved in propan-2-ol (5 ml) and concentrated hydrochloric acid added to pH 2. Evaporation to dryness gave a white solid (m.p. 233-236°C). The white solids were combined and recrystallised from propan-2-ol to yield N-methyl-l-[l(3,4-dichlorophenyl)cyclobutylJbutylamine hydrochloride (m.p. 236-237°C) (Formula I n = 0; R£ = propyl; Rg = H; R3 = H; R^ = Me; R5 = 4-C1 and Rg = 3-Cl). - 35 In a similar manner to that described above the following compounds were prepared. Where the formyl starting material was insoluble in ether, a solution of the reducing agent was added to a stirred suspension of the formyl compound. As the size of the group R-^ is increased the hydrochloride salts of the desired compounds become less soluble in the aqueous phase and more soluble in the organic phase so that appropriate modifications in the isolation procedure are required as will be apparent to those skilled in the art.
ExampleR1R5R6 m.p. 9(a) isopropyl Cl H 257-259° 9(b) sec-butyl Cl H 209-212° 9(c) isobutyl Cl H 225-233° 9(d) cyclopentyl Cl H 252-256° 9(e) n-hexyl Cl H 117-118° 9(f) 4-methoxyphenyl Cl H 264-266° 9(g) 3-methoxyphenyl Cl H 254-255° 9(h) 2-methoxyphenyl Cl H 149-153° 9(i) cyclohexyl Cl H 170-172° 9(a) isobutyl -(CH = ch)2- 256-259° 9(k) cyclohexyl Cl C1 223-224° 9(1) isobutyl Me Me (1) 9(m) propyl OMe H 173-175° 9(n) methyl phenyl H 116-118° (1) Boiling point of free base >150° atl.O mm Hg.
Example 10 The product of Example 7 (4 g), diethyleneglycoldimethyl ether (25,ml), water (10 ml) and concentrated hydrochloric acid (10 ml) were mixed and heated under - 36 reflux for nine hours. The solution was washed with ether and aqueous NaOH added before an ether extraction was performed. The ether extract was washed with brine and water and yielded an oil on evaporation. The oil (3.19 g) was dissolved in a mixture of propan-2-ol (4 ml) and ether (20 ml) and concentrated hydrochloric acid (1.5 ml) added. The solvent was evaporated in vacuo. Repeated dissolution in industrial methylated spirit and evaporation in vacuo gave a gum which solidified on warming in vacuo. The pro10 duct was recrystallised from petroleum ether (b.p. 100120°C) and had a melting point of 201-203°C. The product was l-[l-(3»4- R5 = 4-C1 and Rg = 3-C1).
In a similar manner to that described above the following compounds were prepared. As the size of the group R^ is increased the hydrochloride salts of the desired compounds become less soluble in the aqueous phase and more soluble in the organic phase so that appropriate modifications in the isolation procedure are required as will be apparent to those skilled in the art.
Example 10(a) 10(h) 10(c)R1 isopropyl sec-butyl isobutylR5 Cl Cl ClR6 H H H m.p. 200-202° 178-179° 163-165° 10(d) cyclopentyl Cl H 185-210°(dec) 10(e) phenyl Cl H 271-276° 10(f) 4-methoxyphenyl Cl K 214-219° 10(g) cyclohexyl Cl H 206-210° 10(h) isobutyl H H 210-212° 10(i) cyclopropyl Cl H 204-206° 53768 EixampleR1R5R6 m.p. 10(3) propyl Ph H 235-236° 10 (k) propyl Me Cl 214-217° 10(1) propyl -(CH=CH)„- 157-159° 10 (m) cycloheptyl Cl H 156-162° 10(n) cyclohexyl Cl Cl 215° 10(p) methyl Cl F 215-217° 10(q) propyl OMe H 178-179° 10(r) propyl Cl F 186-188° 10( s) propyl Cl H 174-175° 10(t) cyclohexylmethyl Cl H 148-150° 10 (u) cyclopropylmethyl Cl H 184-185° 10(v) propyl -CH=CH-CC1=CH- (a) 10(w) propyl H CF 126-128° 10(x) 4-fluorophenyl Cl H 279° 10(y) (b) methyl :C^CH=CH- 248-262° cl, ΪΗ1 ibi boiling point of free base 168°C/O.O5 mm Hg. diethyleneglycoldimethyl ether replaced by ethyleneglycoldimethyl ether.
In a similar manner to that described above, l-[l-(4chloro-2-fluorophenyl)cyclobutylJbutylamine (b.p. 99°C/0.05 mm Hg) (Formula I n = 0; R^ = propyl; Rg, R^ and R^ = H; R^ = 4-C1: Rg = 2-F), l-[1-(2-fluorophenyl)cyclobutylJbutylamine hydrochloride (m.p. 175-177°C). (Formula I n = 0; R^ = propyl; R2, Ry R^, Rj = H and Rg = 2-F) and l-[l-(4-chloro-2-methyl) cyclobutylJbutylamine hydrochloride (m.p. 188-190°C) (Formula I n = 0; R]_ = propyl; Rg, R^ and R^ = H; R^ = 4-C1 and Rg = 2-Me) were prepared as Examples 10(z),10(aa) and 10(bb) Example 11 respectively.
The product of Example 10(c) (3.3 g) in the form of the free base, formic acid (2.99 g) and water (1 ml) were mixed with cooling. 37-40% Aqueous formaldehyde (3-93 ml) was added and the mixture heated for eighteen hours at a temperature of 85-95°C. Excess dilute hydrochloric acid was added and the solution evaporated to dryness. The residue was basified with 5N sodium hydroxide solution and the product was extracted into ether. Evaporation of the ether yielded a pale yellow oil which was dissolved in a mixture of propan-2-ol (4 ml) and ether (20 ml) and concentrated hydrochloric acid (2 ml) was added dropwise. The solution was evaporated and the residue dissolved repeatedly in ethanol and evaporated in vacuo to give a gum which was triturated with petroleum ether (b.p. 60-80°) to yield a yellow solid which was recrystallised from acetone. The product was N,N-dimethyl-l-[l-(4-chlorophenyl)cyclobutyr33-methylhutylamine hydrochloride (m.p. 195-197°C). (Formula I n = 0; R-j. = isohutyl; Rg = H; R^, R^ = Me; Rg = 4-C1; R6=H).
In a similar manner to that described above the following compounds of Formula I were prepared CHR.NMeo.HCl Example Starting *1R5R6 m.p. Material 11(a) 10(h) isobutyl H H 195-198° H(h) 10(d) propyl Ph H 194-196° 11(c) 10 (n) cyclohexyl Cl Cl 227-228° 11(d) 10(q) propyl OMe H 187-188° 11(e) 10(s) propyl Cl H 194-196° 11(f) io(t) cyclohexyl methyl Cl H 194-196° 11(g) 10 (u) cyclopropyl methyl Cl H 165-167° 11(h) 10(v) propyl -CH=CH-CC1=CH- (a) ll(i) isohutyl Cl Cl 225-226° ll(j) 10(x) 4-fluorophenyl Cl H 234° ll(k) propyl isopropyl H 211-213° (a) boiling point of free base <250°C/0.05 mm Hg. Example 11(l) In a similar manner to that described above N,Ndimethyl-l-[l-(4-chloro-2-fluorophenyl)cyclobutyl] butylamine hydrochloride (m.p. 183°) was prepared.
(Formula I n = 0; R^ = propyl; Rg R5 = 4-C1; Rg = 2-F) H; R, Me; - 39 Example 12 The product of Example 7 (8.3 g), diethyleneglycoldlmethyl ether (50 ml), water (20 ml) and concentrated hydrochloric acid (20 ml) were mixed and heated under reflux for sixteen hours. The mixture was poured into water, aqueous NaOH was added and the product extracted into ether. Evaporation gave a dark oil. A sample of this oil (7-9 g), water (0.7 ml) and formic acid (6.5 ml) were mixed and formaldehyde (6.5 ml) added. The mixture was heated under reflux for three hours and then concentrated hydrochloric acid (10 ml) and propan-2-ol (10 ml) were added. Evaporation to dryness gave N,N-dimethyl-l-[l-(3,4dichlorophenyl)cyclobutylJbutylamine hydrochloride (m.p. 195-196°) as a white solid (Formula I n = 0; = propyl; R2 = H; R?, R4 = Me; Rg = 4-C1 and Rg = 3-Cl).
Example 13 1-(4-Chlorophenyl)-l-cyclobutanecarbonitrile (37.6 g) prepared in a similar manner to the 1-(3,4-dichlorophenyl)1-cyclobutanecarbonitrile described in Example 1 was added to a solution of potassium hydroxide (32.4 g) in diethyleneglycol (370 ml) and the mixture heated under reflux for three and a half hours. The reaction mixture was poured into an ice/water mixture and the resulting solution was washed with ether. The aqueous layer was added to a mixture of concentrated hydrochloric acid (100 ml) and ice and the resulting precipitate of 1-(4-chlorophenyl)-1cyclobutanecarboxylic acid (m.p. 86-88°) collected, washed with water and dried.
A solution of the acid (10.5 g) prepared as above in tetrahydrofuran (150 ml) was added dropwise under nitrogen to a stirred suspension of lithium aluminium hydride (2 g) in tetrahydrofuran (150 ml). The mixture was stirred under reflux for two hours and water added. The mixture was filtered through diatomaceous earth (CELITE - TM) and the product extracted into ether. After washing with water and drying, the ether was evaporated to give a residue - 40 which was recrystallised from petroleum ether (b.p. 6080°). The product was l-[l-(4-chlorophenyl)cyclobutyl]methyl alcohol (m.p. 60-62°C).
A solution of the alcohol prepared as described above 5 (60 g) in pyridine (52 ml) was added dropwise to a solution of p-toluenesulphonylchloride (60 g) in pyridine (100 ml) cooled in ice. The temperature was allowed to rise to room temperature and remain there for eighteen hours. l-tl-(4Chlorophenyl)cyclobutyljmethyl p-toluene sulphonate (m.p. 99-100°C) was precipitated by pouring the reaction mixture into a mixture of ice and concentrated hydrochloric acid (200 ml).
A solution of the sulphonate compound (97 g) prepared as described above and sodium cyanide (16.6 g) in dimethyl sulphoxide (370 ml) was heated on a steam bath for eighteen hours. The mixture was poured into water and extracted with ether. After washing and drying the ether was evaporated to leave a solid residue of 2-[l-(4-chlorophenyl)~ cvclobutyllacetonitrile (m.p. 63-65°C).
A solution of di-isopropylamine (16.5 g) in dry tetrahydrofuran (50 ml) was stirred under nitrogen at a temperature of 0°C and a 1.6 M solution of n-butyllithium in hexane (100 ml) added dropwise. The reaction mixture was stirred for 30 minutes and then cooled to -78°C. A solu25 tion of 2-[l-(4-chlorophenyl)cyclobutyl]acetonitrile (9.5 g) prepared as described above in dry tetrahydrofuran (25 ml) was added dropwise. The temperature of the mixture was allowed to rise to 0°C and the mixture was stirred for ten minutes before a solution of methyl iodide (10 ml) in tetrahydrofuran (10 ml) was added. Tetrahydrofuran (75 ml) was added to give a homogeneous solution and a further solution of methyl iodide (4 ml) in tetrahydrofuran (10 ml) added. The mixture was stirred at ambient temperature for two hours and then water (50 ml) added. The aqueous phase was washed with ether and the ether combined with the organic phase of the reaction mixture. The combined organic 53768 - 41 phases were washed three times with 5N hydrochloric acid, three times with water, dried and evaporated to yield an oil which solidified and was recrystallised from industrial methylated spirit to give 2-[l-(4chlorophenyl)cyclobutyl]-2-methylpropionitrile (m.p. 73-75°C).
The nitrile prepared above (4 g) was heated under reflux with potassium hydroxide (8 g) in diethyleneglycol (40 ml) for 24 hours. The reaction mixture was cooled, added to water (50 ml) and the aqueous phase washed twice with ether. The aqueous phase was acidified with 5N hydrochloric acid and extracted with three portions of ether.
The combined ether extracts were washed with water, dried and evaporated to give a white solid which was recrystallised from petroleum ether (b.p. 60-80°) to give 2-Cl(4-chlorophenyl)cyclobutylJ-2-methylpropionic acid (m.p. 95110°C).
Oxalyl chloride (10 ml) was added to the acid (2 g) prepared as above and after the initial effervescence had subsided the mixture was heated under reflux for one hour. Excess oxalyl chloride was removed by distillation and the residual oil added to concentrated aqueous ammonia (75 ml).
An oily solid formed which was extracted into ethyl acetate. The extract was washed with water, dried and evaporated to give 2-(l-(4-chlorophenyl)cyclobutyl]-2-methyl propionamide.
The amide prepared as above (1.34 g) was dissolved in a mixture of acetonitrile (8 ml) and water (8 ml) and iodosobenzene bistrifluoroacetate (3.4 g) added and the mixture stirred at ambient temperature for five and a half hours.
Water (75 ml) and concentrated hydrochloric acid (8 ml) were added and the mixture extracted with ether. The ether extract was washed with 5N hydrochloric acid and the aqueous phase basified and extracted with further portions of ether which were dried and evaporated to give an oil.
The oil was dissolved in petroleum ether (b.p. 80-100°) and dry hydrogen chloride gas passed through the solution. - 42 1-tl-(4—Chlorophenyl)cyclobutyl]-l-methylethylamine hydrochloride (m.p. 257-259°C) was collected by filtration (Formula I n = 0; R^, Rg = Me; Rg, R^ = H; Rg = 4-C1; Rg = H).
Example 14 The product of Example 4(h) (3.4 g) was mixed with anhydrous sodium formate (0.72 g), 98% formic acid (10 ml) and 37-40% aqueous formaldehyde solution (5 ml) and the mixture heated at a temperature of 85-95°C for sixteen hours. The mixture was diluted with water (50 ml) and basified to pH 10 with aqueous sodium hydroxide solution. The basic aqueous solution was extracted with ether, washed with water and dried with magnesium sulphate. Dry hydrogen chloride gas was bubbled through the ether extract to give a white precipitate of N,N-dimethyl-l-[l-(4-chloro-3-trifluoromethylphenyl)cyclobutyl]ethylamine hydrochloride (m.p. 246-247°C) (Formula I n=0; R^ = Me; Rg = H; Rg, R^ = Me; Rg = 4-C1 and Rg =3-CFg).
Example 15 The production of salts of the compounds of the invention is illustrated by the following Examples in which equimolar amounts of the base and the acid were taken up in a solvent. The salt was then obtained from the solution by conventional techniques. Example Base Acid Solvent m.p. of salt 15(a) 10(s) citric aqueous acetone 158-160° 15(b) 10(s) maleic ether 155-157° 15(c) 10(s) succinic ether 152-153° 15(d) 2 L(+)tartario I.M.S. 150-153° 15(e) Note (a) citric ether/methanol 163-164°(dec) (a) The base was 1-Cl—(3,4—dimethylphenyl)cyclobutyl]-3- methylbutylamine prepared in a similar manner to that described in Example 10. 53768 - 43 Example 16 A solution of bromobenzene (15.7 g) in ether (50 ml) was added dropwise with cooling to magnesium turning (2.4 g) under an atmosphere of nitrogen. A solution of l-(4-chlorophenyl)-cyclobutanecarbonitrile (19.1 g) prepared in a similar manner to that described in Example 1 for the 1-(3,4-dichlorophenyl )cyclobutane carbonitrile in ether (50 ml) was added and the ether replaced by dry toluene (130 ml). The reaction mixture was heated on a steam bath for one hour. A sample (20 ml) of the resulting solution was added to a solution of sodium borohydride (1 g) in diethyleneglyooldimethyl ether (60 ml) and the mixture was stirred for one and a half hours. Water (60 ml) was added slowly and the aqueous layer extracted with toluene. The toluene extracts were washed with water, dried and evaporated to give a residue which was dissolved in methanol (50 ml). 6N Hydrochloric acid (5 ml) was added and the solution filtered and evaporated. Trituration with dry acetone gave a-[l-(4-chlorophenyl)cyclobutyl]benzylamine hydrochloride (m.p. 277-279°C) (Formula I n=0; R^Ph; R2= H; R3,R4=H; R5=4-C1; R6=H).
Example 17 Methyl formate (62 ml) was added dropwise to isopropylamine (85.5 ml) with stirring at a rate which maintained gentle reflux conditions. Stirring was continued for two hours after the addition. Methanol was distilled off at 100°C and N-isopropylformamide (b.p. 108-109°C/25 mm Hg) obtained by distillation. l-Acetyl-l-(4-ohlorophenyl)cyclobutane (10.4 g) prepared in a similar manner to that described in Example 1 for 1acetyl-l-(3,4-dichlorophenyl)oyclobutane and 98% formic acid (5 ml) were added to N-isopropylformamide (43.5 g) and the mixture heated at 180°C for four hours. Excess starting material was distilled off under reduced pressure (20 mm Hg) to leave a viscous residue which was heated under reflux with concentrated hydrochloric acid (30 ml) for six hours. The reaction mixture was washed with ether until a colourless solution was obtained. The aqueous phase was basified, extracted with ether, dried and evapo68 -44-rated to give an oil which was dissolved in 5N hydrochloric acid. On evaporation a yellow oil was obtained which was triturated with petroleum ether (b.p. 62-68°C) to give N-isopropyl-l-Il-(4-chlorophenyl)cyclobutyl] ethylamine hydrochloride (m.p. 170-174°C) (Formula I n = 0; R^ = Me; Rg = H; Rg = isopropyl; R4=H; Rg =4-Cl; *6 = H>· Example 18 l-Acetyl-l-(3,4-dichlorophenyl)cyclobutane (7.0 g) prepared as described in Example 1 was slowly added to a mixture of pyrrolidine (25 ml) and 98% formic acid (15 ml) heated to 130-135°C for five hours. The mixture was stirred and heated at 16O-165°C for sixteen hours. After cooling the mixture was poured into 5N hydrochloric acid (200 ml).
The solution was washed with ether, basified with aqueous sodium hydroxide solution and extracted with ether. The ether extract was washed with water, dried and hydrogen chloride gas was passed into the extract which was then evaporated to dryness. The residue was triturated with dry ether to give a solid which was recrystallised from propan-2-ol to give N-l-[l-(3,4-dichlorophenyl)cyclobutyl] ethyl pyrrolidine hydrochloride (m.p. 233-235°C) (Formula I n = 0; R^ = Me; Rg = H; Rg and R^ together with the nitrogen to which they are attached form a pyrrolidine ring; Rg = 4-C1 and Rg = 3-Cl).
Example 19 l-(4-Chlorophenyl)-l-cyclobutane carboxylic acid (10.5 g) prepared as described in Example 13 was heated under reflux with thionyl chloride (20 ml)for 2¾ hours. Excess thionyl chloride was evaporated off and the acid chloride of the above acid distilled (b.p. 82-9β°/0.2 mm Hg).
A solution of the acid chloride (23.0 g) in dry tetrahydrofuran (100 ml) was added slowly to the product of the reaction of magnesium turnings (3.0 g) and ethyl bromide (12.0 g) in dry tetrahydrofuran at a temperature of -70 to - 45 -60°C. The temperature was kept at -60°C for an hour and was then allowed to rise to 0°C. Water (50 ml) was added followed by 5N hydrochloric acid (150 ml) with cooling. The reaction mixture was extracted with ether, washed with water, sodium bicarbonate solution, dried. The solvent was removed by evaporation and l-propionyl-l-(4-chlorophenyl)cyclobutane obtained by distillation (b.p. 96-104°C/0.25 mm) The ketone produced above was converted to N,N-dimethyl1-[l-(4-chlorophenyl)oyclobutylpropylamine hydrochloride (m.p. 213-215°C) in a similar manner to that described in Example 12 (Formula I n = 0; = Et; R2 = H; Rg, R4 = Me; Rg = 4-C1; Rg = H).
Example 20 l-Acetyl-l-(4-chlorophenyl)cyclobutane (61 g prepared in a similar manner to that described in Example 1 for 1acetyl-l-(3,4-dichlorophenyl)cyclobutane, platinum oxide (0.75g), 33% solution of methylamine in ethanol (60 g) and ethanol (30 ml) were charged into an autoclave. The autoclave was filled with hydrogen and maintained at about 60°C and bar pressure for ten hours. The reaction mixture was filtered through charcoal and the solids washed with absolute alcohol. The solvents were removed by evaporation and a sample of the residue (10 g) was shaken with 2M hydrochloric acid (50 ml) and ether (50 ml). The aqueous layer was basified and extracted with ether. The ether extract yielded a liquid on evaporation which was distilled (1O9°C/O.3 mm Hg) to give N-methyl-1-tl-(4-chlorophenyl) cyclobutylJethylamine (Formula I n=0; R^ = Me; R2 = H; Rg = Me; R^ = H; Rg = 4-C1 and Rg = H).
Example 21 Sodium borohydride (2.0 g) was added to solution of 1-[1-(3»4-dichlorophenyl)oyclobutyl]ethylamine (1.5 g prepared by treating the product of Example 1 with aqueous sodium hydroxide) in glacial acetic acid (30 ml). The mixture was heated at 95-100°C for sixteen hours and then cooled. Aqueous sodium hydroxide solution was added and the reaction mixture extracted with ether. The ether extract was shaken with 5N hydrochloric acid and the aqueous layer was washed with ether, basified and extracted with ether. Hydrogen chloride gas was passed into the ether extract which was evaporated to dryness. Trituration with acetone gave N-ethyl-1[1-(3,4-dichlorophenyl)cyclobutyljethylamine hydrochloride (m.p. 211-212°C). (Formula I n = 0; = Me; Rg = H; R3 = Et; R4 = H; Rg = 4-C1 and Rg = 3-C1.) Example 22 A mixture of N-ethyl-1-[1-(3,4-dichlorophenyl) cyclobutyljethylamine (0.5 g prepared hy treating the product of Example 21 with aqueous sodium hydroxide) and acetic anhydride (1 ml) was heated at 40-45°C for thirty minutes. The reaction mixture was basified and extracted with ether.
The ether extract was washed, dried and evaporated to give N-acetyl-N-ethyl-l-[l-(3,4-dichlorophenyl)cyclobutyl] ethylamine as an oil.
This oil was dissolved in tetrahydrofuran (10 ml) and borane-dimethyisulphide complex (0.5 ml) added dropwise.
The reaction mixture was stirred at room temperature for two hours and then heated to 35-40°C for thirty minutes.
After cooling the reaction mixture was basified and extracted with ether. Hydrogen chloride gas was passed into the dried ether extract which was evaporated to dryness. Trituration with ether gave N,N-diethyl-l-[l-(3,4dichlorophenyl)cyclobutyljethylamine hydrochloride (m.p. 199-201°C). (Formula I n = 0; R^ = Me; Rg = H; Ry R4 = Et; Rg = 4-C1 and Rg = 3-C1.) - 47 Example 23 A mixture of 1-acetyl-l-(3,4-dichlorophenyl) cyclohutane (2.2 g) prepared as described in Example 1, ammonium acetate (7 g),sodium cyanoborohydride (0.4 g) and methanol (28 ml) was stirred at room temperature for four days. The reaction mixture was poured into a mixture of ice and water and the resulting mixture extracted with ether. The ether extract was washed with water, dried and the ether removed to leave 1-[1-(3,4-dichlorophenyl) cyclobuty!jethylamine as an oil which was identified by standard analytical techniques as the compound of Example 1 in the form of its free base.
Example 24 A mixture of l-acetyl-l-(3»4-dichlorophenyl)cyclobutane (4.86 g) prepared as described in Example 1, hydroxylamine hydrochloride (1.6 g), sodium acetate trihydrate (3-5 g), industrial methylated spirit (15 ml) and water (2 ml) was heated under reflux for twenty hours. The cooled reaction mixture was poured into water and the oil which separated was cooled to give a solid which was recrystallised from industrial methylated spirit to give 1-acetyl-l-(3,4dichlorophenyl)cyclobutane oxime (m.p. 120-121°C).
A solution of the oxime prepared above (4.0 g) in ether (50 ml) was added slowly to a stirred suspension of lithium aluminium hydride (0.9 g) in ether (50 ml) under nitrogen. The mixture was heated under reflux for one hour and, after cooling, water and then a 20% aqueous solution of Rochelle's salt.(potassium sodium tartrate tetrahydrate) (27 ml) and a 10% aqueous solution of sodium hydroxide (6 ml) added.
The reaction mixture was stirred for one hour and then continuously extracted with ether during eighteen hours.
The ether extract was dried and the ether removed to leave a solid from which l-[1-(3,4-dichlorophenyl)cyclobutyl] ethylamine was separated by high pressure liquid chromatography. The product was identified by standard - 48 2768 analytical techniques as the compound of Example 1 in the form of its free base.
Example 25 A 1M solution of diisobutylaluminohydride in hexane (200 ml) was added tinder nitrogen to a solution of 1-phenyl-l-cyclobutane carbonitrile (31.4 g) in ether (100 ml) at a temperature below -30°C. The temperature was maintained below O°C for thirty minutes and 5N hydrochloric acid (200 ml) at a temperature of -10°C added.
The reaction mixture was washed with petroleum ether (b.p. 60-80°C) and then warmed to 40°C. The reaction mixture was extracted with petroleum ether (b.p. 60-80°C) and the extract dried and evaporated to yield 1-phenyl-l-eyclobutane-carbaldehyde as an oil.
Methylamine was bubbled through a solution of the aldehyde (9.4 g) prepared as above in toluene (100 ml) whilst the temperature of the reaction mixture was maintained below 0°C. Magnesium sulphate (20 g) which had been dried over a flame and then cooled under nitrogen was added to the reaction mixture which was left for sixteen hours at room temperature before being filtered. The toluene was then removed by evaporation and the residue dissolved in ether (50 ml). This solution was added to a solution of propyllithium prepared by slowly adding excess propyl bromide (12.8 g) to a suspension of lithium (1.26 g) in ether (50 ml). The resulting mixture was left for sixteen hours at room temperature. A trace of unreacted lithium was removed by filtration and the filter washed with ether, water and then 5N hydrochloric acid. The filtrate and washings were heated on a steam bath for one hour. After cooling the reaction mixture was washed with ether and the aqueous layer was basified using aqueous sodium hydroxide solution. The reaction mixture was extracted with ether and the extract dried and the ether removed to give a residue from which N-methyl-l-(lphenylcyclobutyl)butylamine (b.p. 80-86°/0.1 mm Hg.) - 49 S2768 was distilled.
The amine (2.3 g) prepared as described above was dissolved in ether (40 ml) and hydrogen chloride gas passed through the solution to precipitate N-methyl-l-(lphenylcyclobutylJbutylamine hydrochloride (m.p. 196-197°C). (Formula I n = 0; = propyl; Rg = H; R^ = Me; R^, and Rg are H.) Example 26 A solution of 1- (3-chloro-5-metbylphenyl)-l-cyclobutanecarbonitrile (8.0 g) in ether (40 ml) was added to a solution of propyl magnesium bromide [prepared by the reaction of 1-bromopropane (6.7 g) and magnesium (1.3 g)] in ether (80 ml) and the mixture heated under reflux for two and a half hours. Two thirds of the ether was evaporated off and then, after cooling, a solution of sodium borohydride (3.5 g) in ethanol (150 ml) added. The mixture was maintained at 50°C for one hour and water (50 ml) and then 5N hydrochloric acid (50 ml) added. The ether layer was separated, dried and evaporated to yield a solid which was recrystallised from propan-2-ol to give l-[l- (3-chloto-5-metiiylphenyl)cyclctouty37butylamine hydrochloride (m.p. 145-146°C).
The hydrochloride salt prepared as above was shaken with ether and 5N sodium hydroxide solution and the ether layer evaporated to give the primary amine which was -converted into N,N-dimethyl-l-[l-(3-chloro-5-itethylphenyl) cyclobutyl]butylamine hydrochloride (m.p. 148°C) (Formula I n = 0; R^ = propyl; Rg = H; R^ and = Me; = 3-C1 and Rg = 5-Me) in a similar manner to that described in Example 2. - 50 53768 Example 27 l-(4-Chlorophenyl)-l-cyclobutanecarbonitrile (37.6 g) prepared in a similar manner to the 1-(3,4-dichlorophenyl)1-cyclobutanecarbonitrile described in Example 1 was added to a solution of potassium hydroxide (32.4 g) in diethyleneglycol (370 ml) and the mixture heated under reflux for three and a half hours. The reaction mixture was poured into an ice/water mixture and the resulting solution was washed with ether. The aqueous layer was added to a mix10 ture of concentrated hydrochloric acid (100 ml) and ice . and the resulting precipitate of l-(4-chlorophenyl)-lcyclobutanecarboxylic acid (m.p. 86° - 88°C) collected, washed with water and dried.
A solution of the acid (10.5 g) prepared as above in tetrahydrofuran (150 ml) was added dropwise under nitrogen to a stirred suspension of lithium aluminium hydride (2 g) in tetrahydrofuran (150 ml). The mixture was stirred under reflux for two hours and water added. The mixture was filtered through diatomaceous earth (CELITE - TM) and the product extracted into ether. After washing with water and drying, the ether was evaporated to give a residue which was recrystallised from petroleum ether (b.p. 60 80°). The product was 1-[l-(4-chlorophenyl)cyclobutyl3methyl alcohol (m.p. 60 - 62°C).
A solution of the alcohol prepared as described above (60 g) in pyridine (52 ml) was added dropwise to a solution of p-toluenesulphonylchloride (60 g) in pyridine (100 ml) cooled in ice. The temperature was allowed to rise to room temperature and remain there for eighteen hours. l-[l-(43o Chlorophenyl)cyclobutyl3methyl p-toluene sulphonate (m.p. 99 - 100°C) was precipitated by pouring the reaction mixture into a mixture of ice and concentrated hydrochloric acid (200 ml). - 51 A solution of the sulphonate compound (97 g) prepared as described above and sodium cyanide (16.6 g) in dimethyl sulphoxide (370 ml) was heated on a steam bath for eighteen hours. The mixture was poured into water and extracted with ether. After washing and drying the ether was evaporated to leave a solid residue of 2-[l-(4-chlorophenyl)cyclobutyljacetonitrile (m.p. 63 - 65°C).
The acetonitrile prepared above (20 g) was dissolved in ether (120 ml) and the solution added dropwise under nitrogen to a stirred suspension of lithium aluminium hydride (5.84 g) in ether (80 ml). The mixture was stirred at ambient temperature for one and a half hours and then under reflux for a further two hours. Water was added dropwise and the resulting mixture filtered through diatomaceous earth. The residue was washed with ether. The filtrate was extracted with ether and the combined ether portions were washed with water and extracted with 5N hydrochloric acid. The acid solution was washed with ether and aqueous NaOH was added. The product was extracted into ether and the extract washed with water, dried and evaporated to give a residue which on distillation gave 2-[l-(4-chlorophenyljcyclobutyljethylamine (b.p. 119 121%. 5 mm Kg).
The ethylamine prepared as described above (6.9 g), formic acid (6.6 ml), water (0.9 g) and 37 to 40% aqueous formaldehyde solution (9 ml) were heated on a steam bath for eighteen hours. The mixture was cooled and excess concentrated hydrochloric acid added. A yellow solid residue was obtained on evaporation to dryness. The solid was partitioned with dichloromethane and 5N sodium hydroxide solution and the aqueous layer extracted with a further portion of dichloromethane. The dichloromethane portions were combined, washed with water, dried and evaporated to yield a solid residue which was dissolved in propan-2-ol (15 ml) and concentrated hydrochloric acid was added to pH 2. The mixture was evaporated to dryness and the residue recrystallised from ethyl acetate to give colourless crystals of N,N-dimethyl-2-[l-(4-chlorophenyl)cyclobutyljethylamine - 52 S2768 hydrochloride (m.p. 220-222°C) (Formula 1 n = 1; R^, Rg = H; Rg, R^ = Me; Rg - 4-C1; Rg, R? and Rg = H).
In a similar manner to that described above the following compounds were made ExampleR5R6 m.p. of HC1 salt 27(a) Cl Cl 218-220° 27(h) I H 263-265° 27(c) -CH=CH - CH=CH- 234-236° 27(d) In a similar manner N,N-dimethyl-2-[1-(4-chloro-2- fluorophenyl)cyclohutyljethylamine hydrochloride (m.p. 232-233°C (dec)) was prepared.
Example 28 2-[l-(4-Chlorophenyl)cyclohutylJethylamine (12 g) prepared as described in Example 27, 1,4-dibromobutane (12.4 g) and anhydrous sodium carbonate (14.3 g) were mixed in xylene (100 ml) and the mixture heated under reflux with stirring for sixteen hours. The mixture was cooled, filtered and the xylene removed by evaporation to give a residue which on distillation gave N-2-El-(4-chlorophenyl)cyclobutylJethylpyrrolidine (b.p. 148-15O°/1.5 mm Hg) (Formula 1 n = 1; R^,Rg = ^3 31X11 R4 together with the nitrogen atom forming a pyrrolidine ring; Rg = 4-C1; Rg, Ry and Rg = H)„ In a similar manner to that described above the following compounds were made and isolated as their hydrochloride salts.
.HC1 Example 28(a) 28(b) R5 R6 Cl Cl -CH=CH-CH=CHm.p. of HCl salt 213° 232-233° Example 29 A solution of 2-[l-(4-chlorophenyl)cyclobutyl]acetonitrile (30 g) prepared as described in Example 27 in ether (100 ml) was added to the reaction product of methyl bromide gas and magnesium turnings (5-95 g) in ether (80 ml). The mixture was heated under reflux for four hours. Ice and then concentrated hydrochloric acid (105 ml) were added and the mixture heated under reflux until all solid material had dissolved. The aqueous layer was washed with ether and the ether used for washing was combined with the ether phase of the reaction mixture. The combined ether extracts were washed with water, dried and evaporated to yield a residue which was distilled twice to yield 1—El—(4-chlorophenyl )cyclobutyl]propan-2-one (b.p. 133-136°/2.5 mm Hg).
The ketone prepared as described above (5.4 g) was mixed with N-methylformamide (18 ml), 98% formic acid (4 ml) and 25% aqueous methylamine (0.6 ml) and the mixture heated under reflux for sixteen hours. The mixture was poured into water and extracted with dichloromethane. The extract.was washed, dried and evaporated to give a residue which was heated under reflux with concentrated hydrochloric acid (10 ml) for six hours. The mixture was evaporated to dryness and the residue dried by repeated addition and vacuum evaporation of an industrial methylated spirit/ toluene mixture. The solid residue was recrystallised from propan-2-ol to give N-methyl-2-[l-(4-chlorophenyl)cyclobutyll-l-methylethylamine hydrochloride (m.p. 193194°C) (Formula I n = 1 R^, Rg = H; Rg = Me; R4 = H; Rg = 4-C1; Rg = H; R? = Me; RQ = H). 53768 - 54 Example 3° A mixture of l-[l-(4-chlorophenyl)cyclobutyl]propan2-one prepared as described in Example 29 (15 g) and 93% formic acid (4 ml) was added dropwise to formamide (12 ml) at 16O°C. The temperature was raised.to 180°C and maintained at this temperature for ten hours. The mixture was cooled, diluted with water and extracted with dichloromethane. The extract was washed, dried and evaporated to yield a yellow oil which was hydrolysed with concentrated hydrochloric acid under reflux. The resulting aqueous solution after dilution with water was washed with ether, aqueous NaOH was added and the aqueous solution extracted with ether. The extracts were washed, dried and evaporated to yield a residue which on distillation gave 2-[l-(4-chlorophenyl)cyclobutyl]-l-methylethylamine (b.p. 105-107°/0.7 mm Hg).
The amine obtained above (2.65 g) was dissolved in propan-2-ol (15 ml) and concentrated hydrochloric acid added dropwise until the pH was 2. Ether (110 ml) was added and colourless crystals of 2-[l-(4-chlorophenyl)cyclobutyl]-l-methylethylamine hydrochloride (m.p. 184185°C) were collected. (Formula I n = 1; R^, R2 = H; Rg, R4 = H; Rg = 4-C1; Rg = H; R? = Me and Rg = H).
Example 31 2-Cl—(4-Chlorophenyl)cyclohutyl]-l-methylethylamine (3.94 g) prepared as described in Example30, 1,4-dibromobutane (3.82 g), anhydrous sodium carbonate (4.4 g) and xylene (30 ml) were mixed and heated under reflux for sixteen hours. The mixture was cooled, filtered and evaporated to yield a residue which was distilled twice (b.p. 130132°/0.5 mm Hg). The product of the distillation was dissolved in propan-2-ol (5 ml) and ether (70 ml) and concentrated hydrochloric acid added to pH 2. The solution was evaporated in vacuo and the residue recrystallised from ethyl acetate to give N-^2-[l-(4-chlorophenyl)cyclobutyl]1-methyl^ethylpyrrolidine hydrochloride (m.p. 151-152°C) (Formula I n=l; RpRg=H; Rg and R^ together with the nitrogen atom forming a pyrrolidine ring; Rg = 4-C1; Rg = H; R? = Me; Rg = H).
Example 52 1- [l-(4-chlorophenyl)cyclobutyl]propan-2-one prepared as described, in Example 29 (25 g) and 98% formic acid (10 ml) were added to formamide (22 ml) at 16O°C. The temperature was raised to 175°0 and maintained at this temperature for sixteen hours. The mixture was cooled, extracted with dichloromethane. The extract was washed with water and evaporated to give a gum which was crystallised from petroleum ether (b.p. 40-60°C) to give N-formyl-2-tl(4-chlorophenyl)cyclobutyl]-l-methylethylamine (m.p. 71-73°C).
N-formyl-2-El-(4-chlorophenyl)cyclobutyl]-l-methylethylamine (11.06 g) prepared as described above was heated under reflux for six hours with a mixture of concentrated hydrochloric acid (34 ml), water (34 ml) and diethyleneglycoldimethyl ether (40 ml). The mixture was cooled, washed with ether and basified with aqueous sodium hydroxide. The basified solution was extracted into ether, washed with water, dried, evaporated and distilled to give 2-Cl-(4chlorophenyl)cyclobutyl3-1-methylethylamine (b.p. 119-121°C at 0.8 mm Hg). The amine (2.65 g) was dissolved in propan-2ol (15 ml) and concentrated hydrochloric acid added to pH 2. Ether (110 ml) was added and crystals of 2-[l-(4-chlorophenyl) cyclobutyl3-1-methylethylamine hydrochloride (m.p. 184-185°C) were collected. (Formula I n = 1; Rp Rg = H; Rg, R^ = H; Rg = 4-C1; Rg = H; Ry = Me and Rg = H.) Example 53 2- [l—(4-Chlorophenyl)cyclobutyl3-1-methylethylamine (1.8 g) prepared as described in Example 32 was mixed with formic acid (4.5 ml). 37 to 40% Aqueous formaldehyde solution (6 ml) was added and the mixture heated first at 45-50°C for 30 minutes and then under reflux for two hours. The mixture was cooled, basified with aqueous sodium hydroxide, extracted with ether, the ether extract was washed with water and extracted with 5N hydrochloric acid. The acid ex'tract was washed with ether, basified - 56 with aqueous sodium hydroxide, and extracted with ethor. Hydrogen chloride gas was passed through the ether extract and a white solid was formed. The solid was collected and recrystallised from ethyl acetate to give N,N-dimethyl2- El- (4-chlorophenyl )cyclobutyl j-l-methylethylamine hydrochloride (m.p. 108-110°C) (Formula I n = Ij = H; r4 = Μθ» Rjj ~ 4-C1; Rg = H; Ry = Me; Rg = H).
Example 54 A 70% solution of sodium bis(2-methoxyethoxy) aluminium hydride in toluene (sold under the trade mark Red-al)(35 ml) was added dropwise to a solution of N-formyl2-[l-(4-chlorophenyl)cyclobutylj-l-methylethylamine prepared as described, in Example 32 (5 g) in dry ether (110 ml) with cooling to maintain the temperature at less than 10°C. The temperature was allowed to rise to about 25°C and then the mixture was heated under reflux for two hours. The reaction mixture was poured into a mixture of crushed ice and concentrated hydrochloric acid. The resulting mixture was washed with ether, basified with aqueous sodium hydroxide and extracted with ether. The ether extract was washed with brine, dried and evaporated to give a liquid which was dissolved in petroleum ether (b.p. 40-60°C). Hydrogen chloride gas was bubbled through the solution to precipitate a solid which was recrystallised from propan-2-ol to give N-methyl-2-[l-(4-chlorophenyl)cyclobutylj-l-methylethylamine hydrochloride (Formula I n = 1; R^, Rg = H; Rg = H; R^ = Me; Rg = 4-C1; Rg = H; Ry = Me and Rg = H) (m.p. 192-194°C). Example 35 A solution in ether (80 ml) of 2-[l-(3,4-dichlorophenyl )cyclobutyl jacetonitrile (23 g) prepared in a similar manner to that described in Example 27 for 2-Cl-(4-chlorophenyl) cyclobutyl jacetonitrile was added to the product of the reaction between magnesium turnings (3· 53 g) and ethyl bromide (10.8 ml) in dry ether (80 ml) with stirring whilst heating on a steam bath. The ether was removed and replaced with toluene and the mixture heated under reflux S3768 - 57 10 for one hour. Water was added and the mixture added to a mixture of ice and concentrated hydrochloric acid. The mixture was heated on a steam bath for one hour and filtered through a diatomaceous earth sold under the Trade Mark CELITE. The filtrate was extracted with dichloromethane and the extract washed with water and sodium bicarbonate solution and dried. The solvent was removed by evaporation and the residue distilled to give 1-(1-(3,4-diohlorophenyl )cyclobutyl]butan-2-one (b.p. 149-15O°/1.1 mm Hg).
The ketone prepared as above was converted into 1-^(1-(3,4-dichlorophenyl)cyclobutyl]methyl^propylamine hydrochloride (m.p. 225-226°C) (Formula I n = 1; Rp Rg, Ry R4 = H; Rg = 4-C1; Rg = 3-Clj R? = Et; Rg = H) in a similar manner to that described in Example 32.
In a similar manner to that described above 2-(1-(3,4dichlorophenyl )cyolobutyl]-l-methylethylamine hydrochloride (m.p. 179°C) (Example 35a Formula I n = 1; Rp Rg, Rg and R^ = H; Rg = 4-C1; Rg = 3-Cl; R? = Me and RQ = H) was prepared.
Example 36 In a similar manner to that described in Example 33 compounds prepared in a similar manner to that described in Example 35 were converted into the corresponding N,N-dimethyl compounds.
Example Starting MaterialR5R6 **7 m.p. 36(a) 35 Cl Cl Et 177-178' 36(b) 35(a) Cl Cl Me 204-205' Example 37 In a similar manner to that described in Example 34, N-formyl compounds prepared as described in Example 32 from ketones prepared as in Example 35 were converted into the corresponding N-methyl compounds.
Example 37(a) (b) Cl H Efc Cl Cl Et HCI m.p. 170-172° 193-194° Example 38 15 A mixture of 2-[l-(4-chlorophenyl)cyclobutyl]acetonitrile (10.1 g) prepared as described in Example 27 , potassium hydroxide (8.1 g) and diethyleneglycol (92 ml) was heated under reflux for three and a half hours. The mixture was poured into an ice/water mixture and the resulting solution washed three times with ether and added to a mixture of ice and concentrated hydrochloric acid. On cooling a solid product separated which was recrystallised from petroleum ether (h.p. 62-68°C) with the use of charcoal. The recrystallised product was 2-[l-(4-chlorophenyl)25 cyclobutyl]acetic acid (m.p. 83-84°C). - 59 The acid (5 g) prepared as described above was added to thionyl chloride (20 ml) and heated under reflux for one hour. Excess thionyl chloride was then removed and the residue poured into a solution of piperidine (3.8 g) in ether (20 ml). The mixture was stirred for thirty minutes and then water was added to dissolve piperidine hydrochloride. The ether layer was separated and the aqueous layer washed with ether. The combined ether portions were washed with water, dried and evaporated to yield a brown io oil which was purified by distillation (b.p. 168°/1 mm Hg) and crystallisation from petroleum ether (b.p. 40-60°C).
The solid product was N-2-[l-(4-chlorophenyl)cyclobutylΙβο etylpiperi dine (m.p. 66-67°C).
A solution of the compound prepared as described above (2.7 g) in ether (20 ml) was added dropwise to a stirred mixture of lithium aluminium hydride (0.7 g)and ether under a nitrogen atmosphere. Stirring was continued for one hour at room temperature and then during heating under reflux for two hours. After cooling in ice, excess lithium alu20 minium hydride was decomposed by the addition of water.
The mixture was filtered through diatomaceous earth (CELITE). The aqueous portion of the filtrate was washed with a portion of ether and this portion was combined with ether portions which had been used to wash the solid residue. The combined ether portions were washed with water, dried and evaporated. The residue was purified by distillation. The product was N-2-[l-(4-chlorophenyl)cyclobutyl]ethy]piperidine (b.p. 152-156°/1.5 mm Hg) (Formula n = 1; R^, Rg = H; Rg and R^ together with the nitrogen atom forming a piperi30 dine ring; Rg = 4-C1; Rg, R? and Rg = H).
In a similar manner to that described above the following compounds were made and isolated as their hydrochloride salts by bubbling dry hydrogen chloride gas through a solution of the base in petroleum ether (b.p. 62-68°C). - 60 Example 38(a) 38(b) 38(c) Cl Cl Cl -Oi-Me -O m.p.(°C) 167-169° 281-283° (dec) 246-248° Example 39 A mixture of sodium hydride (9 g), mineral oil (9 g) and dry dimethylformamide (150 ml) was stirred under nitrogen at 0°C. A solution of n-toluenesulphonylmethyl iso10 cyanide which is sold under the trade name TosMIC (24.6 g) in dimethylformamide (50 ml) was added over twenty minutes. Absolute alcohol (18 g) was then added to the mixture at 0°C over a period of one hour. l-Acetyl-l-(4-chlorophenyl)~ cyclobutane (24 g) prepared in a similar manner to that described in Example 1 for l-acetyl-l-(3,4-diohlorophenyi)cyclobutane dissolved in dry dimethylformamide (20 ml) was added and the mixture was stirred for sixteen hours during which the temperature rose to ambient temperature. The mixture became viscous and petroleum ether (b.p. 80-100°C) (25 ml) was added. The mixture was poured into water and the pH adjusted to 6 by the addition of 5N hydrochloric acid. The resulting mixture was extracted with ether and the ether extract washed with water, dried and partially evaporated. A brown solid separated and was removed by filtration and the filtrate was evaporated and 2-Cl—(4-chlorophenyl)cyclobutylIpropionitrile (b.p. 128136°/0.6 mm Hg) collected by distillation. 53768 - 61 A solution of the propionitrile prepared as described above (3.5 g) in dry ether (20 ml) was added dropwise to a stirred mixture of lithium aluminium hydride (0.9 g) in dry ether (20 ml) at a temperature in the range 15 to 20°C.
The mixture was stirred at ambient temperature for two hours and then during heating under reflux for a further three hours. 5N Sodium hydroxide solution (20 ml) and water (50 ml) were added and the mixture filtered through diatomaceous earth (CELITE). The filter medium was washed with ether and the washings combined with the ether of the reaction mixture. The combined extracts were extracted with 5N hydrochloric acid. A solid formed at the interface which was collected by filtration, washed with acetone and dried. The solid was 2-[l-(4-chlorophenyl)cyclobutyl]15 propylamine hydrochloride (m.p. 210-230°C).
The hydrochloride salt (1.0 g) prepared as above was dissolved in water, 5N aqueous sodium hydroxide solution was added and the solution extracted with ether. The ether extract was dried and evaporated to yield an oil which was heated under reflux for six hours with 1,4-dibromobutane (0.82 g), anhydrous sodium carbonate (0.96 g) and xylene (6.5 ml). The mixture was cooled, filtered through diatomaceous earth (CELITE) and evaporated to dryness. The residue was dissolved in propan-2-ol (10 ml) and concentra25 ted hydrochloric acid (5 ml) added. The mixture was evaporated to dryness and the residue collected, washed with ether and dried. The product was N-2-[l-(4-chlorophenyl)cyclobutylJpropylpyrrolidine hydrochloride (m.p. 238248°C) (Formula I n = 1; = Me; R2 = H; Rg and R^ together with the nitrogen to which they are attached forming a pyrrolidine ring; Rg = 4-C1; Rg, R? and Rg = H). - 62 Example 40 A solution of 1-(3,4-dichlorophenyl)-l-cyclobutane carbonitrile (70 g) prepared in a similar manner to that described in Example 1 in industrial methylated spirit (200 ml) was mixed with a solution of sodium hydroxide (3.7 g) in water (5 ml) and 30% hydrogen peroxide solution added dropwise. The mixture was heated at 50°C for one hour and then stirred with 10% palladium on charcoal (0.5 g) for one hour. The mixture was filtered and evaporated to dryness to give 1-(3,4-dichlorophenyl)-l-cyclobutanecarboxamide.
The carboxamide prepared above was dissolved in dioxane (500 ml) and concentrated hydrochloric acid (100 ml) and then a solution of sodium nitrite (35 g) in water (80 ml) were added dropwise. The mixture was heated at 85 to 95°C for sixteen hours and then poured into water. The mixture was extracted with ether and the extract back-extracted with aqueous potassium carbonate. The basic extract was washed with ether and acidified with concentrated hydrochloric acid to give 1-(3,4-dichlorophenyl)-1cyclobutanecarboxylic acid (m.p. 120-121°C).
The acid prepared as above was converted into the compound of Example 27(a) in a similar manner to that described in Example 27and to the compound of Example 28(a) in a similar manner to that described in Example 28.
Example 41 A solution of 2-Cl~(3,4-dichlorophenyl)cyclobutyl3acetonitrile (23 g prepared in a similar manner to 2[l-(4-chlorophenyl)cyclobutyl3acetonitrile described in Example27) in dry ether (50 ml) was added to a solution of ethyl magnesium bromide prepared by the dropwise addition of ethyl bromide (15-83 g) in dry ether (80 ml) to a stirred mixture of magnesium turnings (3-53 g) and ether (80 ml). The mixture was heated under reflux for 30 minutes and stirred without further heating for 16 hours and then under reflux for a further two hours. - 63 1-El-(3.4-dichlorophenyl)cyclobutyl]-2-butaniminyl magnesium bromide was collected by filtration and a sample of the solid (about 1 g) was added to a solution of sodium borohydride (3 g) in diethyleneglycoldimethyl ether (30 ml). The mixture was stirred at 45°C for 90 minutes. The reaction mixture was extracted with 5N hydrochloric acid. The aqueous phase was basified with aqueous sodium hydroxide solution and extracted with ether. The ether extract was dried and hydrogen chloride gas passed into the extract to precipitate 1-^[l-(3,4-dichlorophenyl)cyclobutyljmethyljpropylamine hydrochloride (m.p. 223-224°C) (Formula I n = 1; Rp Rg* R3 and R4 = H; Rg = 4—Cl; Rg = 3—Cl; Ry — Et; Rg = H).
Example 42 IS Formic acid (7 ml) was added dropwise to pyrrolidine (15 ml) at a temperature in the range 135-l40°C. 1-[1-(3,4dichlorophenyl)cyclobutyl]butan-2-one (3 g) prepared as described in Example 35 was added dropwise and the mixture heated at 14O°C for one hour. The temperature was raised to 185-190°C for sixteen hours. The reaction mixture was cooled and poured into 5N hydrochloric acid. The solution was washed with ether, basified and extracted with ether. The ether extract was dried and hydrogen chloride gas passed into the extract. Evaporation to dryness gave a solid which was triturated with dry ether and recrystallised from a mixture of petroleum ether and propan-2-ol to give N-l-£[l-(3»4dichlorophenyl)cyclobutyljraethyljpropylpyrrolidine hydrochloride (m.p. 157-l60°C) (Formula I n = 1; Rp Rg = H; Rg and R4 together with the nitrogen atom forming a pyrrolidine ring; Rg = 4-C1; Rg = 3-C1; Ry = Et and Rg = H). 53768 - 64 Example 43 1-tl-(3,4-dichlorophenyl)cyclobutyl]-2-butaniminyl magnesium bromide (25 g) prepared as described m Example 41 was heated at 9O-95°C for two hours with a mixture of concentrated hydrochloric acid (20 ml) and water (30 ml). The reaction mixture was extracted with ether and the ether extract dried and evaporated to dryness. 1-(1-(3,4-dichlorophenyl)cyclobutyl]butan-2one (b.p. 122-124° at 0.1 mm Hg) was distilled.
A mixture of 1-(1-(3,4-dichlorophenyl)cyclobutyl]butan2-one (4.3 g) prepared as described above, hydroxylamine sulphate (2.65 g), sodium acetate (4.0 g), industrial methylated spirit (56 ml) and water (23 ml) was stirred at ambient temperature for sixteen hours. The reaction mixture was extracted with ether. The ether extract was washed with water, dried and evaporated to give a solid which was recrystallised from petroleum ether (b.p. 80-100°C) to give l-[l-(3,4-dichlorophenyl)cyclobutyl]butan-2-one oxime (m.p. 106-110°C).
A solution of trifluoroacetic acid (2.33 ml) in tetrahydrofuran (5 ml) was added to a stirred suspension of sodium borohydride (1.13 g) in tetrahydrofuran (30 ml) over a period of five minutes. A solution of the oxime (1.7 g) prepared as described above in tetrahydrofuran (25 ml) was added dropwise and the mixture heated under reflux for six hours. The mixture was cooled and water (25 ml) and then 5N sodium hydroxide solution (25 mljwere added. The mixture was extracted with ether and the extract washed with water, dried and evaporated to give a residue which was dissolved in petroleum ether (25 ml). Dry hydrogen chloride gas was passed through the ether solution to give l-£(l~(3,4-dichlorophenyl) cyclobutylJmethyl^propylamine hydrochloride (m.p. 222-224°C). (Formula I n = 1; R^, Rg, Rg and R^ = H; Rg = 4-C1; Rg = 3-Cl; Ry = Et and Rg = H). 53768 - 65 Example 44 A solution of l-[l-(3,4-dichlorophenyl)cyclobutyl] butan-2-one (5.0 g) prepared as described in Example 43 and methoxy-amine hydrochloride (1.63 g) in a mixture of pyridine (60 ml) and ethanol (60 ml) was heated under reflux for 72 hours. The reaction mixture was evaporated to dryness and a mixture of water and ether added to the residue. The ether layer was washed with sodium bicarbonate solution and water, dried and evaporated to give l-[l-(3,4lo dichlorophenyl)cyclobutyl]butan-2-one oxime O-methyl ether.
The oxime ether prepared as described above (15 g) was then reduced to the product of Example 43 using sodium borohydride (0.95 g) ih a similar manner to that described in Example 43· Example 45 Sodium cyanoborohydride (0.4 g) was added to a solution of 1-[1-(3,4-dichlorophenyl)cyclobutyl]butan-2-one (2.45 g) prepared as described in Example 42 and ammonium acetate (7 g) in methanol (28 ml) and the mixture stirred at room temperature for four days. Water (25 ml) was added dropwise with cooling. The aqueous mixture was extracted with ether and the ether layer washed with water and 5N hydrochloric acid (50 ml). The compound of Example 43 precipitated as a white solid.
Example 46 2-[l-(4-Chlorophenyl)cyclobutyl]acetic acid (1.5 g prepared as described in Example 38 ) was heated under reflux with thionyl chloride. Excess thionyl chloride was removed in vacuo and the residue added dropwise to a 3o solution of cyclopropylamine (0.94 g) in ether (10 ml) and the mixture stirred for thirty minutes. Water was added and the aqueous phase extracted with ether. The ether extract was dried and the ether removed to give 2-[1-(4chlorophenyl )cyclobutyl]-N-cyclopropylacetamide. 53768 - 66 A solution of the amide prepared as above (1.45 g) in ether (15 ml) was added dropwise to a stirred suspension of lithium aluminium hydride (0.42 g) in ether (7.5 ml) under nitrogen. The mixture was stirred at ambient temperature for one hour and then heated under reflux for a further two hours. After cooling, water (0.45 ml), then 15% sodium hydroxide solution (0.45 ml) and then water (1.35 ml) were added and the mixture stirred for fifteen minutes. The mixture was filtered and extracted with ether.
The ether extract was shaken with N hydrochloric acid and a solid formed in the aqueous layer. The solid was N-cyclopropyl-2-[l-(4-chlorophenyl)cyclobutyljethylamine hydrochloride (m.p. 166-17O°C).
A mixture of the hydrochloride salt (0.41 g) prepared as described above, sodium formate (0.1 g), 98% formic acid (1 ml) and 37-40% aqueous formaldehyde solution (0.5 ml) was heated at 85-90°C for eighteen hours. The reaction mixture was cooled and extracted with ether. The ether extract was washed with water, dried and filtered. Hydrogen chloride gas was passed through the filtrate which was then warmed to give a solid which was N-cyclopropyl-N-methyl-2[l-(4-chlorophenyl)cyclohutylJethylamine hydrochloride (m.p. 149-153°C). (Formula I n = 1; R1 and Rg = H; Rg = cyclopropyl; R^ = Me; Rg = 4-C1; Rg, R? and Rg = H).
Example 47 Pharmaceutical compositions containing any one of the compounds of formula I disclosed in Examples 1 to 46 are prepared in the following manner. 53768 - 67 Example ( a) Tablets are prepared from the following ingredients: Parts by Weight Active Ingredient 50.0 Lactose 78.5 Polyvinylpyrrolidone 5.0 Maize Starch 15.0 Magnesium Stearate 1.5 The active ingredient, the lactose and some of the io starch are mixed and granulated with a solution of the polyvinylpyrrolidone in ethanol. The granulate is mixed with the magnesium stearate and the rest of the starch and the mixture is compressed in a tabletting machine to give tablets containing 50.0 mg. of the active ingredient.
Example ^7(b) Capsules are prepared in the following way. A mixture • of the active ingredient (45 parts by weight) and lactose powder (205 parts by weight) is filled into hard gelatin capsules, each capsule containing 45 mg- of the active ingredient.
Example 47(c) In the preparation of enteric coated tablets, the tablets described in Example 47 (a) are given a thin coat of shellac varnish, followed by 20 coats of cellulose acetate phthalate in a manner well -known in the art. In a similar manner the capsules of EXQjpple 47 (b) may be provided with an enteric coating.
Example. ^7( d) Vials containing a solution of water-soluble compounds of the present invention suitable for injection are prepared from the following ingredients: 53768 Active Ingredient 1100 g.
Mannitol 1100 g.
Water, freshly distilled to 11 litres The active ingredient and mannitol are dissolved in 5 some of the water and the volume of the solution is adjusted to 11 litres. The resulting solution is sterilised by filtration and filled into sterile vials each containing 1.65 ml. of solution.
Example 47(e) In the preparation of suppositories, 100 parts by weight of the finely ground active ingredient is incorporated in 1214 parts by weight of triglyceride suppository base and the mixture is formed into suppositories each containing 100 mg. of the active ingredient.
In the preceding Examples novel ketones of formula V have been disclosed in which R^, Rg and Rg have the meaning given in Examples 1, 1(a) to 1(e), 3, 4, 4(a) to 4(e), 6, 7, 7(a) to 7(d) 9, 9(a) to 9(n), 10, 10(a) to 10(z), 10(aa), 10(bb), ll(i), ll(k) and ll(l). These novel ketones of formula V are prepared by hydrolysis of novel imines of formula XVI in which Y = MgBr and R1S Rg and Rg have the meaning given in the Examples specified above.
In the preceding Examples novel ketones of formula VI have b?en disclosed in which R1, R^, Rg, Rg and Ry have the meaning given in Examples 29, 35, 36 and 43. These novel ketones of formula VI were prepared by hydrolysis of novel imines of formula XVIII in which Y = MgBr and R^, R2, Rg, Rg and Ry have the meaning given in Examples 29, 35, 36 and 43. 3o In the preceding Examples novel cyano compounds of formula XVII are disclosed in which Rg and Rg have the meaning given in Examples 1, 1(d), 1(e), 4(g), 9(e), 9(m), 10(k), 10(e), 10(p), 10(r), 10(v), 10(y), 10(z), 10(aa), 10(bb), ll(k), 11(1) and 26. - 69 52768 In the preceding Examples novel formamides of formula XXV are disclosed in which R^, R^, Rg, Rg, R^, Rg and n have the meaning given in Examples 1, 1(a) to 1(e), 3, 4, 4(a) to 4(e), 6, 7, 7(a) to 7(d), 9, 9(a) to 9(n), 10, (a) to 10(z), 10(aa), 10(bb), ll(i), ll(k), ll(l), 29, 32, 35 and 36.

Claims (49)

1. ) Compounds of formula 1 R, k 5 rfR l R 2 ^ R 7 R 8 n^3 R 4 in which n = 0 or 1; 5 in which, when n = 0, R-^ is a straight or branched chain alkyl group containing 1 to 6 carbon atoms, a cycloalkyl group containing 3 to 7 carbon atoms, a cycloalkylalkyl group in which the cycloalkyl group contains 3 to 6 carbon atoms and the alkyl group contains 1 to 3 carbon atoms, an alkenyl 10 group or an alkynyl group containing 2 to 6 carbon atoms or a group of formula II II H, halo or an alkoxy group containing 1 to 3 carbon atoms; 15 in which, when n = 1, R^ is H or an alkyl group containing 1 to 3 carbon atoms; in which Rg is H or an alkyl group containing 1 to 3 carbon atoms; in which and R^, which are the same or different, are 20 H, a straight or branched chain alkyl group containing 1 to 4 carbon atoms, an alkenyl group having 3 to 6 carbon atoms, an alkynyl group having 3 to 6 carbon atoms, a cycloalkyl group in which the ring contains 3 to 7 carbon atoms, a group of formula R in CO where R 11 is H or R^ and R^ together 25 with the nitrogen aton to which they are attached form an optionally substituted heterocyclic ring having 5 or 6 atans in the ring which optionally contains further hetero atans in addition to the nitrogen atcm; 53768 - 71 in which Rg and Rg> which are the same or different, are H, halo, trifluoromethyl, an alkyl group containing 1 to 3 carbon atoms, an alkoxy or alkylthio group containing 1 to 3 carbon atoms, phenyl or Rg and Rg, together with the carbon atoms to which they are attached, form a second benzene ring optionally substituted by one or more halo, alkyl, or alkoxy grorps containing 1 to 4 carbon atoms or the substituents of the second benzene ring together with the two carbon atoms to which they are attached form a further benzene ring; and in which Ry and Rg which are the same or different are H or an alkyl group containing 1 to 3 carbon atoms; and their pharmaceutically acceptable salts.
2. ) Compounds of formula I as claimed in claim 1, in which n = 0, Rj is a straight or branched chain alkyl group containing 1 to 4 carbon atoms, a cycloalkyl group containing 3 to 7 carbon atoms, a cycloalkylmethyl group in which the cycloalkyl ring contains 3 to 6 carbon atoms or a group of formula II in which Rg and R 1Q are H, fluoro or methoxy and in which Rg is H or methyl. 5) Conpounds of formula I as claimed in claim 2, in which R^. is methyl, ethyl, propyl, iospropyl, butyl, isobutyl, secondary butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclcheptyl, cyclopropylinethyl, cyclobut/lmetlvl, cyclapentylmethyl, cyclohex/hnethyl or phenyl.
3. 4) Compounds of formula I as claimed in claim l,in which n = 1, is H or methyl and Rg is H.
4. 5) Compounds of formula I as claimed in any one of the preceding claims, in which Rg and R 4 are H, methyl, ethyl or formyl. 53768 - 72
5. 6) Compounds of formula I as claimed in any one of claims 1 to 4/in which Rg and R^ together with the nitrogen to which they are attached form a heterocyclic ring containing one nitrogen atom and 4 or 5 carbon atoms which is optionally substituted by one or more alkyl groups, or they form a heterocyclic ring containing a second nitrogen atom which is optionally alkylated or a heterocyclic ring including one or more double bonds.
6. 7) Compounds of formula I in which Rg and R g are H, 10 fluoro, chloro, bromo, iodo, trifluoromethyl, methyl, methoxy, phenyl or Rg and Rg together with the carbon atoms to which they are attached form a second benzene ring optionally substituted by halo.
7. 8) Compounds of formula I as claimed in any one of claims 15 1 or 4 to 8, in which R? is H, methyl or ethyl and Rg is H.
8. 9) Compounds as claimed in claim 1 of formula III CR^gCCRTRg^NRgR^ III in which R.^ Rg, Rg, R^, Rg, R g , r?, r 8 and n are as defined in claim 1.
9. 10) Compounds as claimed in claim 9 in which Rg and Rg, which are the same or different, are H, fluoro, chloro, bromo, iodo, trifluoromethyl, methyl, methoxy, phenyl or R 5 and R g together with the carbon atoms to which they are attached form a second benzene ring optionally substituted by a chloro group. - 73
10. 11) Compounds as claimed in claim 1 of formula IV in which Rp Rg, Rg, R 4 , Rg, Ry, Rg and n are as defined in claim 1 and Rg is fluoro or methyl. 5
11. 12) Compounds of formula IV as claimed in claim 11 in which Rg is H, fluoro, chloro, bromo, iodo, trifluoromethyl, methyl, methoxy or phenyl and in which Rg is fluoro or methyl.
12. 13) Compounds of formula I named in Table I herein. 10
13. 14) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I claimed in any one of the preceding claims.
14. 15) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula III 15 claimed in claim 9 or claim 10.
15. 16) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula IV claimed in claim 11 or claim 12.
16. 17) A pharmaceutical composition as claimed in any one 20 of claims 14, 15 or l6 in unit dosage form.
17. 18) A pharmaceutical composition comprising a therapeutically active amount of a compound claimed in claim 13. - 74
18. 19) A process for the preparation of compounds of formula I comprising the reductive amidation of ketones of formula V to give compounds in which n = 0; Rg = R 4 = CH0 an ^ R^, Rg and Rg are as defined in Claim 1 or of ketones or aldehydes of formula VI cr 1 r 2 cor 7 '3 VI to give compounds in which n = 1; R 4 = CHO, Rg = H and 10 R^, Rg, Rg, Rg and R 7 are as defined in Claim 1, said reductive amidation comprising the reaction of the ketone or aldehyde (a) with formamide and formic acid to give compounds in which Rg is H, (b) with ammonium formate and formic acid to give compounds in which R^ is H, (o) with 15 formamides of formula HCONHRg in which Rg is an alkyl or cycloalkyl group and formic acid or (d) with amines of formula RgNHg in which Rg is an alkyl or cycloalkyl group and formic acid.
19. 20) A process for the preparation of compounds of formula 20 i comprising reductive amination of ketones of formula V R 6 COR^ '3 53768 - 75 to give compounds in which n = 0; R 2 = H and R^, Rg and Rg are as defined in Claim 1 or of ketones or aldehydes of formula VI 5 to give compounds in which n = 1; Rg = H and R^, R 2 , Rg, Rg and R ? are as defined in Claim 1, said reductive amination comprising the reaction of the ketone or aldehyde (a) with an ammonium salt and a reducing agent to give compounds in which R 3 and R 4 are H, (b) with an amine of 10 formula RgNH 2 and a reducing agent to give compounds in which R 4 is H, (c) with an amine of formula R 3 R 4 NH in which neither R 3 nor R 4 are H and a reducing agent or the catalytic reduction of a mixture of the ketone or alkehyde and an amine of formula R 3 R 4 NH in which one or both of Rg and R 4 15 are H, an alkyl group, a cycloalkyl group or in which Rg and R 4 together with the nitrogen to which they are attached form a heterocyclic ring.
20. 21) A process for the preparation of compounds of formula I comprising the reduction of compounds of formula VII Z in which - 76 a) Z is a group of formula -CR=NOH or an ester or ether thereof to give compounds of formula I in which n = 0 and Rg, R 3 and R 4 are H; b) Z is a group of formula -CR^NRg to give compounds of 5 formula I in which n = 0 and R 2 and R 4 are H; c) Z is a group of formula -CR^=NY in which Y represents a metal-containing moiety derived from an organometallic reagent to give compounds of formula I in which n = 0 and R 2 , Rg and R 4 are H; 10 d) Z is a group of formula -CR^RgGN to give compounds of formula I in which n = 1 and Rg, R 4 , R^ and Rg are H; e) Z is a group of formula -CR-jRgCR^NOH or an ester or an ether thereof to give compounds of formula I in which n = 1 and Rg, R 4 and Rg are H; 15 f) Z is a group of formula -CR 1 R 2 CR 7 =NRg to give compounds of formula I in which n = 1 and R 4 and Rg are H; g) Z is a group of formula -CR^R 2 CR 7 =NY in which Y represents a metal-containing moiety derived from an organometallic reagent to give compounds of formula I in which 20 n = 1 and Rg, R 4 and Rg are H; h) Z is a group of formula -CR^RgCONRgR^ to give compounds of formula I in which n = 1 and R ? and Rg are H.
21. 22) A process as claimed in claim 21 in which Y is MgBr or Li. 25
22. 23) A process for the preparation of compounds of formula I comprising (a) the reaction of an organometallic reagent which is a Grignard reagent of formula R^MgBr or an organolithium compound of formula R^Li with an imine of formula VIII »2768 - 77 R 6 ch=nr 3 □ VIII in which R,, R_ and R, are as defined in claim 1 and (b) Jo o the hydrolysis of the resulting product to give compounds of formula I in which n = 0 and R 2 and R^ are H. 5
23. 24) A process for the preparation of compounds of formula I comprising (a) the reaction of an organometallic reagent which is a Grignard reagent of formula R^MgBr or an organolithium compound of formula R^Li with an imine of formula IX in which R 3 , R 5 and R g are as defined in claim 1 and (b) the hydrolysis of the resulting product to give compounds of formula I in which n = 1 and and Rg are H.
24. 25) A process for the preparation of compounds of formula I 15 comprising the decarboxylative rearrangement of (a) amides of formula X In which R^, R 2 , R g and R g are as defined in claim 1 to give primary amines in which n = 0, - 78 (b) amides of formula XI R c CR.R 0 CR 7 R„CONH« 5 ·. r- ' 12/8 i η 6 Λ3 □ in which Rg, Rg, R g , R? and Rg are as defined in claim 1 to give primary amines in which n = 1, 5 (c) acyl azides formed by reaction of sodium azide with acid chlorides of formula XII in which R^, Rg, Rg and R g are as defined in claim 1 to give primary amines in which n = 0, 10 (d) acyl azides formed by reacting sodium azide with acid chlorides of formula XIII in which R QR-jRgCR-jRgCOCl 1' “2' R 5' λ 6' λ 7 Λ 8 to give primary amines in which n = 1. XIII R- and R o are as defined in claim 1
25. 26) A process for the preparation of compounds of formula I comprising the reaction of hydrazoic acid with (a) carboxylic acids of formula XIV - 79 cr 1 r 2 cooh 'J XIV in which R^, R 2 , Rg and Rg are as defined in claim 1 to give primary amines in which n = 0, or (b) carboxylic acids of formula XV in which R^, R 2 , Rg, Rg, R? and Rg are as defined in claim 1 to give primary amines in which n = 1.
26. 27) A process for the preparation of compounds of formula I in which R^ is H comprising the hydrolysis of compounds of 10 formula I in which R^ is CHO.
27. 28) A process for the preparation of compounds of formula I in which R^ is methyl comprising the reduction of compounds of formula I in which R^ is CHO.
28. 29) A process for the preparation of compounds in formula I 15 in which one or both of Rg and is other than H comprising the conversion of a compound of formula I in which one or both of Rg and R^ are hydrogen to the required compound.
29. 30) Compounds of formula I whenever made by a process claimed in any one of claims 19 to 29. 53768 80
30. 31) Compounds of formula XXV R. '6 R. CHO XXV in which R^, R 2 , Rg, Rg, R g , Ry, Rg and n are as defined in claim 1. 5
31. 32) Compounds of formula I described herein with reference to the Examples.
32. 33) Compounds of formula III described herein with reference to the Examples.
33. 34) Compounds of formula IV described herein with reference 10 to the Examples.
34. 35) Compounds of formula XXV described herein with reference to the Examples.
35. 36) Pharmaceutical composition comprising a therapeutically active amount of a compound as claimed in any one of claims 15 32, 33 or 34.
36. 37) A process for preparing compounds of formula I substantially as hereinbefore described with reference to the Examples.
37. 38) 1-/1-(4-chlorophenyl)cyclobuty1/butylamine and its 20 pharmaceutically acceptable salts. - 81
38. 39) N,N-dimethyl-l-/l-(4-chlorophenyl)cyclobuty 2/butylamine and its pharmaceutically acceptable salts.
39. 40) N-methyl-1-/Ϊ-(3,4-dichlorophenyl)cyclobuty1/butylamine and its pharmaceutically acceptable salts. 5
40. 41) N,N-dimethyl-l-/l-(3,4-dichlorophenyl)cyclobuty17butylamine and its pharmaceutically acceptable salts.
41. 42) N-methyl-1-/1-(4-chlorophenyl)cyclobuty 1/-3methylbutylamine and its pharmaceutically acceptable salts. 10
42. 43) N,N-dimethy1-1-/1-(4-chlorophenyl)cyclobuty 1/-3methylbutylamine and its pharmaceutically acceptable salts.
43. 44) N,N-dimethy1-1-/1-(3,4-dichlorophenyl)cyclobuty173-methylbutylamine and its pharmaceutically acceptable 15 salts.
44. 45) 1-/1-(3,4-dichlorophenyl)cyclobuty1/ethylamine and its pharmaceutically acceptable salts.
45. 46) Ν,Ν-dimethyl-1-/1-(3,4-dichlorophenyl)cyclobutyl/ethylamine and its pharmaceutically acceptable salts. 20
46. 47) a-/l-(4-chlorophenyl)cyclobutyj/benzylamine and its pharmaceutically acceptable salts.
47. 48) 1-^/1-(3,4-dichlorophenyl)cyclobutyl/methyl^ propylamine and its pharmaceutically acceptable salts. 53768 - 82
48. 49) Ν,Ν-dimethyl-1-^/1-(3,4-dichlorophenyl)cyclobutyl7methyl^propylamine and its pharmaceutically acceptable salts.
49. 50) Ν,Ν-dimethy1-2-/1-(4-iodophenyl)cyclobutyl7ethyl5 amine and its pharmaceutically acceptable salts.
IE481/82A 1981-04-06 1982-03-03 1-arylcyclobutylalkylamine compounds useful as therapeutic agents IE52768B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8110710 1981-04-06
GB8110709 1981-04-06

Publications (2)

Publication Number Publication Date
IE820481L IE820481L (en) 1982-10-06
IE52768B1 true IE52768B1 (en) 1988-02-17

Family

ID=26279045

Family Applications (1)

Application Number Title Priority Date Filing Date
IE481/82A IE52768B1 (en) 1981-04-06 1982-03-03 1-arylcyclobutylalkylamine compounds useful as therapeutic agents

Country Status (40)

Country Link
KR (1) KR900000274B1 (en)
AT (1) AT382612B (en)
AU (1) AU545595B2 (en)
BG (2) BG40651A3 (en)
CA (1) CA1248955A (en)
CH (1) CH652117A5 (en)
CS (1) CS244672B2 (en)
CY (1) CY1408A (en)
DD (1) DD208348A5 (en)
DE (1) DE3212682A1 (en)
DK (1) DK161770C (en)
ES (5) ES511152A0 (en)
FI (1) FI77223C (en)
FR (1) FR2504920B1 (en)
GB (1) GB2098602B (en)
GE (1) GEP19970661B (en)
GR (1) GR76697B (en)
HK (1) HK13888A (en)
HU (1) HU186582B (en)
IE (1) IE52768B1 (en)
IL (1) IL65257A0 (en)
IN (1) IN155773B (en)
IT (1) IT1235758B (en)
JO (1) JO1184B1 (en)
KE (1) KE3753A (en)
LU (1) LU84070A1 (en)
MY (1) MY8800048A (en)
NL (1) NL192201C (en)
NO (1) NO156785C (en)
NZ (1) NZ200178A (en)
PH (1) PH22762A (en)
PL (2) PL139120B1 (en)
PT (1) PT74580B (en)
RO (2) RO84802B (en)
SE (1) SE452611B (en)
SG (1) SG67287G (en)
SU (2) SU1482522A3 (en)
UA (2) UA7838A1 (en)
YU (2) YU44336B (en)
ZW (1) ZW4982A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
GB8412480D0 (en) * 1984-05-16 1984-06-20 Elliott M Pesticides
DK58285D0 (en) * 1984-05-30 1985-02-08 Novo Industri As PEPTIDES AND MANUFACTURING AND USING THEREOF
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
DK119785D0 (en) * 1985-03-15 1985-03-15 Nordisk Gentofte INSULIN PREPARATION
US5157021A (en) * 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
CA2138998A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
GB9309749D0 (en) * 1993-05-12 1993-06-23 Boots Co Plc Therapeutic agents
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (en) * 1995-05-29 1996-12-05 Basf Ag Use of aryl substituted cyclobutylalkylamines to treat obesity
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
BG65170B1 (en) * 1999-03-17 2007-05-31 Knoll Gmbh Use of n-substituted derivatives of 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine for the production of a medicine for treating eating disorders
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
GB9915617D0 (en) 1999-07-05 1999-09-01 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
AU2002210816A1 (en) * 2000-11-02 2002-05-15 Torrent Pharmaceuticals Ltd Process for preparation of beta-phenethylamine derivative
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
KR100536750B1 (en) * 2002-10-05 2005-12-16 한미약품 주식회사 Pharmaceutical composition comprising crystalline hemihydrate of sibutramine methanesulfonate
FR2870537A1 (en) * 2004-05-19 2005-11-25 Servier Lab NOVEL PROCESS FOR SYNTHESIZING (1S) -4,5-DIMETHOXY-1- (METHYL AMINOMETHYL) BENZOCYCLOBUTANE AND ITS ADDITION SALTS AND APPLICATION TO THE SYNTHESIS OF IVABRADINE AND ITS ADDITION SALTS PHARMACEUTICALLY ACCEPTABLE ACID
KR100606533B1 (en) 2004-08-27 2006-08-01 한올제약주식회사 An improved synthetic method of sibutramine
KR100606534B1 (en) 2004-11-01 2006-08-01 한올제약주식회사 An improved synthetic method of sibutramine
KR100618176B1 (en) * 2004-12-02 2006-09-01 휴먼팜 주식회사 Sibutramine tartrate, its preparation process and phamaceutical composition comprising it
WO2006073292A1 (en) 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
BRPI0716952A2 (en) 2006-09-15 2013-10-29 Reviva Pharmaceuticals Inc COMPOUND, METHODS FOR TREATING AND / OR PREVENTING OBESITY OR CO-MORBID INDICATION RELATED TO OBESITY, AND FOR SYNTHESIZING CYCLOalkylmethylamine Derivatives
CN101555214B (en) * 2008-04-08 2012-07-11 北京嘉事联博医药科技有限公司 Phenylcyclobutylacylamide derivative as well as optical isomer, preparation method and application thereof
FR2935381B1 (en) * 2008-08-29 2010-12-17 Servier Lab NOVEL METHOD FOR THE RESOLUTION OF ENANTIOMERES OF (3,4-DIMETHOXY-BICYCLOO-4.2.0-OCTA-1,3,5-TRIEN-7-YL) NITRILE AND APPLICATION TO THE SYNTHESIS OF IVABRADINE
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
SI2496583T1 (en) 2009-11-02 2015-02-27 Pfizer Inc. Dioxa-bicycloš3.2.1ćoctane-2,3,4-triol derivatives
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
RU2642074C2 (en) * 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Compositions, synthesis and methods for application of phenylcycloalkylmethylamine derivatives
FR2993561B1 (en) * 2012-07-17 2014-10-31 Servier Lab PROCESS FOR ENZYMATIC SYNTHESIS OF (7S) -1- (3,4-DIMETHOXY BICYCLO [4.2.0] OCTA-1,3,5-TRIENE 7-YL) N-METHYL METHANAMINE, AND APPLICATION TO THE SYNTHESIS OF THE IVABRADINE AND ITS SALTS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (en) * 1960-02-12 1962-03-01 Hoechst Ag Process for the preparation of analeptically active phenylcycloalkylmethylamines
US3526656A (en) * 1967-05-25 1970-09-01 Parke Davis & Co (1-arylcyclobutyl)carbonyl carbamic acid derivatives

Also Published As

Publication number Publication date
ES519031A0 (en) 1984-08-16
ES8305678A1 (en) 1983-04-16
ZW4982A1 (en) 1982-11-03
NL8201347A (en) 1982-11-01
SE452611B (en) 1987-12-07
ES519030A0 (en) 1984-08-01
ES8406413A1 (en) 1984-08-01
AU8221382A (en) 1982-10-14
PL139120B1 (en) 1986-12-31
KR900000274B1 (en) 1990-01-24
FI821197L (en) 1982-10-07
ATA132582A (en) 1986-08-15
IT1235758B (en) 1992-09-28
HK13888A (en) 1988-02-26
AT382612B (en) 1987-03-25
GB2098602A (en) 1982-11-24
ES519029A0 (en) 1984-08-01
HU186582B (en) 1985-08-28
YU44336B (en) 1990-06-30
FR2504920B1 (en) 1985-06-28
NL192201C (en) 1997-03-04
BG40651A3 (en) 1986-01-15
SG67287G (en) 1988-02-19
SU1482522A3 (en) 1989-05-23
CH652117A5 (en) 1985-10-31
FR2504920A1 (en) 1982-11-05
DK161770C (en) 1992-02-10
IL65257A0 (en) 1983-12-30
ES8406414A1 (en) 1984-08-01
RO89436A2 (en) 1986-06-30
PT74580B (en) 1983-12-23
RO84802B (en) 1984-10-30
AU545595B2 (en) 1985-07-18
FI821197A0 (en) 1982-04-05
KE3753A (en) 1987-10-02
DE3212682A1 (en) 1982-10-21
PL235832A1 (en) 1983-09-12
YU6385A (en) 1985-08-31
MY8800048A (en) 1988-12-31
ES511152A0 (en) 1983-04-16
RO84802A (en) 1984-09-29
NZ200178A (en) 1985-07-31
IN155773B (en) 1985-03-09
SU1461372A3 (en) 1989-02-23
ES8403097A1 (en) 1984-03-01
SE8202166L (en) 1982-11-25
DE3212682C2 (en) 1992-03-26
NO156785C (en) 1987-11-25
CS245782A2 (en) 1985-08-15
UA7589A1 (en) 1995-09-29
YU75082A (en) 1985-08-31
GEP19970661B (en) 1997-01-04
NO156785B (en) 1987-08-17
NO821087L (en) 1982-10-07
NL192201B (en) 1996-11-01
DD208348A5 (en) 1984-05-02
FI77223C (en) 1989-02-10
ES519032A0 (en) 1984-03-01
PL240079A1 (en) 1983-09-12
JO1184B1 (en) 1983-11-30
FI77223B (en) 1988-10-31
GB2098602B (en) 1984-08-22
UA7838A1 (en) 1995-12-26
PL136242B1 (en) 1986-02-28
PT74580A (en) 1982-04-01
GR76697B (en) 1984-08-28
IE820481L (en) 1982-10-06
IT8248157A0 (en) 1982-04-02
LU84070A1 (en) 1983-06-07
KR830010065A (en) 1983-12-26
BG40652A3 (en) 1986-01-15
CY1408A (en) 1988-04-22
DK161770B (en) 1991-08-12
PH22762A (en) 1988-12-12
ES8407002A1 (en) 1984-08-16
CS244672B2 (en) 1986-08-14
CA1248955A (en) 1989-01-17
DK146482A (en) 1982-10-07
YU44253B (en) 1990-04-30

Similar Documents

Publication Publication Date Title
IE52768B1 (en) 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
US4522828A (en) Therapeutic agents
AU2007205114B2 (en) Cycloalkylamines as monoamine reuptake inhibitors
US3532749A (en) N&#39;-propargyl-n**2-cyclopropyl-ethylenediamines and the salts thereof
US3365458A (en) N-aryl-n&#39;-cyclopropyl-ethylene diamine derivatives
CS258149B2 (en) Method of arylcyclobutylalkylamines production
US4443449A (en) Arylcyclobutylalkylamines and anti-depression composition and methods using same
US4035512A (en) Aminotetralols
CZ295747B6 (en) Substituted benzylamines and pharmaceutical composition
US4833143A (en) Antidepressant amines
NO132865B (en)
US4104402A (en) 5,6-Dihydroxy aminotetralol compounds
JPH0665163A (en) Substituted ethylamine, its production, its use as pharmaceutical and synthesis intermediate
US3978130A (en) 1-Cyclopropyl-1-phenyl-ω-amino-1-alkanols
DE2836674A1 (en) ALPHA -HALOGEN METHYLAMINE
MX2008008807A (en) Cycloalkylamines as monoamine reuptake inhibitors
SI8210750A8 (en) Therapeutical agents - process for obtaining (1- arylcyclobutyl) alkylamine
CS244675B2 (en) Production method of(-arylcyclobutyl)alkamines

Legal Events

Date Code Title Description
SPCF Request for grant of supplementary protection certificate

Free format text: SPC 025/2001, 20011115, EXPIRES: 20020304

SPCR Supplementary protection certificate rejected

Spc suppl protection certif: SPC025/2001

Filing date: 20011115

SPCR Supplementary protection certificate rejected

Spc suppl protection certif: SPC025/2001

Filing date: 20011115